2,4,6-Trisubstituted pyrimidine compounds as ATR kinase inhibitors

2,4,6-trisubstituted pyrimidine compounds are developed to inhibit ATR kinase, addressing the lack of effective treatments for ATR kinase-mediated diseases by enhancing cancer therapy efficacy with reduced side effects.

CN115551860BActive Publication Date: 2024-12-06BEIJING TIDE PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180034352.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-04-19
Filing Date
2021-05-20
Publication Date
2024-12-06
Estimated Expiration
2041-05-20

AI Technical Summary

Technical Problem

Existing treatments for ATR kinase, such as cancer, are not effective and there are no inhibitors on the market to target ATR kinase specifically, leading to challenges in treating ATR kinase-mediated diseases like cancer without significant side effects on normal cells.

Method used

Development of 2,4,6-trisubstituted pyrimidine compounds that inhibit ATR kinase, which can be used alone or in combination with chemotherapy or radiotherapy to enhance treatment efficacy while minimizing toxicity to normal cells.

Benefits of technology

The compounds effectively target ATR kinase, enhancing the treatment of proliferative diseases like cancer, including solid tumors and leukemias, with reduced side effects on normal cells and synergistic effects with conventional therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115551860B_ABST
    Figure CN115551860B_ABST
Patent Text Reader

Abstract

Provided are compounds of general formula (I), which can be used to treat ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Also provided are pharmaceutical compositions of compounds of general formula (I), their use for treating ATR kinase-mediated diseases, and their preparation. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to 2,4,6-trisubstituted pyrimidine compounds as inhibitors of ATR kinase. More specifically, the compounds of the present invention can be effectively used for the treatment of ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. The present invention also provides pharmaceutical compositions of the compounds, their use for treating ATR kinase-mediated diseases, and their preparation. Background Art

[0002] ATR (Ataxia telangiectasia and Rad3-related protein) is a type of protein kinase involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR activation can be activated by stalled replication forks or DNA single-strand damage (SSB). Activated ATR will recruit repair proteins or repair factors to repair damaged sites, delaying the mitotic process (especially in the G2 / M phase of mitosis), stabilizing the replication fork and ensuring genome stability.

[0003] In addition, the DNA damage repair system in most tumor cells is abnormal, usually lacking certain repair pathways (such as mutations in p53 or ATM), making them more dependent on ATR for survival. In normal cells, due to their sound and complete repair pathways, inhibiting ATR kinase alone will not have a significant effect. Therefore, inhibiting ATR may have a more significant effect on the treatment of cancer without causing major toxic side effects on normal cells.

[0004] Moreover, the inhibition of ATR can be used in combination with radiotherapy or chemotherapy drugs to synergistically enhance the effect. Widely used chemotherapy drugs include antimetabolites (such as gemcitabine), DNA cross-linking agents (such as cisplatin, carboplatin), alkylating agents (such as temozolomide), topoisomerase inhibitors (such as topotecan, irinotecan), etc. When tumor cells are affected by chemotherapy or radiotherapy, they will activate the ATR signaling pathway to a large extent to repair damaged DNA. Therefore, when using radiotherapy or chemotherapy drugs to treat cancer, inhibiting ATR at the same time can greatly enhance the treatment effect of cancer.

[0005] So far, there is still no ATR inhibitor on the market, so it is still necessary to discover more effective and safe ATR inhibitors. Summary of the invention

[0006] The present invention provides compounds of formula (I) which are useful for treating ATR kinase mediated diseases, such as proliferative diseases, such as cancer.

[0007] In one aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof:

[0008]

[0009] in,

[0010] X is CR X or N;

[0011] Y is CR Y or N;

[0012] R1, R2, R3, R4 and R Y are independently selected from H, D, halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R1 and R2, R3 and R4 are connected to form a bond, C 1-6 Alkylene, C 2-6 Alkenylene or C 2-6 Alkyne; wherein the group may be substituted by one or more D or halogen until fully substituted;

[0013] Where R X is H, D, halogen, -CN, -NRR', -OR, -SR or C 1-6 Alkyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0014] When Y is CR Y When R Y , R1 together with the atoms to which they are attached form C 3-5 Cycloalkyl or 3-5 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0015] Ring A is phenyl or a 5-6 membered heteroaryl group;

[0016] R a independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7Cycloalkyl or 3-8 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0017] m = 0, 1, 2, 3, 4 or 5;

[0018] Ring B is a 5-10 membered heteroaryl group;

[0019] R b independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 3-8 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0020] n=0, 1, 2, 3, 4 or 5;

[0021] R5 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0022] R6 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0023] R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 3-7 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0024] R and R' are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein said group may be substituted by one or more D or halogen until fully substituted;

[0025] p=1 or 2.

[0026] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, and optionally a pharmaceutically acceptable excipient.

[0027] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient, which may also contain another therapeutic agent.

[0028] In another aspect, the present invention provides a kit comprising a compound of the present invention, and other therapeutic agents and a pharmaceutically acceptable carrier, adjuvant or vehicle.

[0029] In another aspect, the present invention provides the use of a compound of the present invention in the preparation of a medicament for treating and / or preventing ATR kinase-mediated diseases.

[0030] In another aspect, the present invention provides a method for treating and / or preventing an ATR kinase-mediated disease in a subject, comprising administering to the subject a compound or composition of the present invention.

[0031] In another aspect, the present invention provides a compound of the present invention or a composition of the present invention for use in the treatment and / or prevention of ATR kinase-mediated diseases.

[0032] In specific embodiments, the disease includes proliferative diseases (such as cancer), especially solid tumors (such as carcinomas and sarcomas) and leukemias and lymphomas, especially for example breast cancer, colorectal cancer, lung cancer (including small cell lung cancer, non-small cell lung cancer and bronchioloalveolar carcinoma) and prostate cancer and bile duct cancer, bone cancer, bladder cancer, head and neck cancer, kidney cancer, liver cancer, gastrointestinal tissue cancer, esophageal cancer, ovarian cancer, pancreatic cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, cervical cancer and vulvar cancer, as well as leukemia [including acute lymphocytic leukemia (ALL) and chronic myelogenous leukemia (CML)], multiple myeloma and lymphoma.

[0033] Other objects and advantages of the present invention will be apparent to those skilled in the art from the following detailed description, examples and claims.

[0034] definition

[0035] Chemical Definition

[0036] Definitions of specific functional groups and chemical terms are described in more detail below.

[0037] When a numerical range is listed, it is intended to include every value and sub-range within the stated range. For example, "C 1-6 "Alkyl" includes C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 and C 5-6 alkyl.

[0038] “C 1-6 "Alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C 1-4 Alkyl groups are preferred. 1-6 Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). The term “C 1-6 "Alkyl" also includes heteroalkyl groups in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkyl group may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents or 1 substituent. Conventional alkyl abbreviations include: Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3) or i-Bu(-CH2CH(CH3)2).

[0039] “C 2-6 "Alkenyl" refers to a straight or branched hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C 2-4 Alkenyl is preferred. 2-6 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. The term “C 2-6"Alkenyl" also includes heteroalkenyl groups in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkenyl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0040] “C 2-6 "Alkynyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and optionally one or more carbon-carbon double bonds. In some embodiments, C 2-4 Alkynyl is preferred. 2-6 Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), hexynyl (C6), and the like. The term “C 2-6 "Alkynyl" also includes heteroalkynyl groups, in which one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). Alkynyl groups may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0041] “C 1-6 Alkylene, C 2-6 Alkenylene or C 2-6 "Alkyne" refers to the above-defined "C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 "Alkynyl" divalent group.

[0042] “C 1-6 "Alkylene" refers to the removal of C 1-6 The other hydrogen of C alkyl forms a divalent group, and may be a substituted or unsubstituted alkylene. 1-4 Alkylene is particularly preferred. Unsubstituted alkylene includes, but is not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylene, for example, alkylene substituted with one or more alkyl (methyl) groups, includes, but is not limited to, substituted methylene (-CH(CH3)-, -C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3) 2-), substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), and the like.

[0043] “C 2-6 "Alkenylene" means removing the C 2-6 In some embodiments, C 2-4 Alkenylene is particularly preferred. Exemplary unsubstituted alkenylene includes, but is not limited to, vinylene (-CH=CH-) and propenylene (e.g., -CH=CHCH2-, -CH2-CH=CH-). Exemplary substituted alkenylene, for example, alkenylene substituted with one or more alkyl (methyl) groups, includes, but is not limited to, substituted ethylene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propenylene (-C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, -CH(CH3)-CH=CH-, -C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), and the like.

[0044] “C 2-6 "Alkynylidene" refers to the removal of C 2-6 The other hydrogen of the alkynyl group forms a divalent group, and may be a substituted or unsubstituted alkynylene group. 2-4 Alkyne is particularly preferred. Exemplary alkynyl includes, but is not limited to, ethynyl (-C≡C-), substituted or unsubstituted propynyl (-C≡CCH2-), and the like.

[0045] “C 1-6 "Alkoxy" refers to a group -OR, where R is a substituted or unsubstituted C 1-6 In some embodiments, C 1-4 Alkoxy is particularly preferred. Specific alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy and 1,2-dimethylbutoxy. The alkoxy group may be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents or 1 substituent.

[0046] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0047] Therefore, “C 1-6 "Haloalkyl" and "C 1-6 "Haloalkoxy" refers to the above-mentioned "C 1-6 Alkyl" and "C 1-6 Alkoxy", which is substituted by one or more halogen groups. In some embodiments, C 1-4 Haloalkyl is particularly preferred, more preferably C 1-2 In some embodiments, C 1-4 Haloalkoxy is particularly preferred, more preferably C 1-2 Halogenated alkoxy. Exemplary haloalkyl groups include, but are not limited to, -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2,2,2-trifluoro-1,1-dimethyl-ethyl, and the like. Exemplary haloalkoxy groups include, but are not limited to, -OCH2F, -OCHF2, -OCF3, and the like. Haloalkyl and haloalkoxy groups may be substituted at any available point of attachment, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0048] “C 3-7 "Cycloalkyl" refers to a non-aromatic cyclic hydrocarbon group having 3 to 7 ring carbon atoms and zero heteroatoms. In some embodiments, C 3-5 Cycloalkyl is preferred. In other embodiments, C 3-6 Cycloalkyl is preferred. In other embodiments, C 5-6 Cycloalkyl is preferred.Cycloalkyl also includes a ring system in which the above-mentioned cycloalkyl ring is fused with one or more aryl or heteroaryl groups, wherein the connection point is on the cycloalkyl ring, and in such a case, the number of carbons continues to represent the number of carbons in the cycloalkyl system. Exemplary cycloalkyls include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), etc. The cycloalkyl group may be optionally substituted by one or more substituents, for example, substituted by 1 to 5 substituents, 1 to 3 substituents or 1 substituent.

[0049] "3-11 membered heterocyclyl" refers to a group of a 3- to 11-membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon. In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as the valence permits. In some embodiments, a 3-9 membered heterocyclyl is preferred, which is a 3-9 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms; in some embodiments, a 3-8 membered heterocyclyl is preferred, which is a 3-8 membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms; a 3-6 membered heterocyclyl is preferred, which is a 3-6 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; a 3-5 membered heterocyclyl is preferred, which is a 3-5 membered non-aromatic ring system having ring carbon atoms and 1 to 2 ring heteroatoms; a 4-8 membered heterocyclyl is preferred, which is a 4-8 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; and a 5-6 membered heterocyclyl is more preferred, which is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms. Heterocyclyl also includes a ring system in which the above-mentioned heterocyclyl ring is fused to one or more cycloalkyl groups, wherein the point of attachment is on the cycloalkyl ring, or a ring system in which the above-mentioned heterocyclyl ring is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring; and in such a case, the number of ring members continues to represent the number of ring members in the heterocyclyl ring system. Exemplary 3-membered heterocyclyls containing one heteroatom include, but are not limited to, aziridine, oxirane, and thiorenyl. Exemplary 4-membered heterocyclyls containing one heteroatom include, but are not limited to, azetidine, oxirane, and thiorenyl. Exemplary 5-membered heterocyclyls containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to, hexahydrotriazinyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thianyl.Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocyclyl groups) include, but are not limited to, dihydroindolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as 6,6-bicyclic heterocyclyl groups) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like. The heterocyclyl group may be optionally substituted with one or more substituents, for example, substituted with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0050] “C 6-10 "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic) 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having 6-10 ring carbon atoms and zero heteroatoms. In some embodiments, aryl has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, aryl has ten ring carbon atoms ("C 10 Aryl also includes ring systems in which the above aryl ring is fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the aryl ring, in which case the number of carbon atoms continues to refer to the number of carbon atoms in the aryl ring system. Aryl groups can be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0051] "5-10 membered heteroaryl" refers to a group of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as the valence permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings. Heteroaryl also includes a ring system in which the above-mentioned heteroaryl ring is fused to one or more cycloalkyl or heterocyclic groups, and the point of attachment is on the heteroaryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the heteroaryl ring system. In some embodiments, 5-6 membered heteroaryl groups are particularly preferred, which are 5-6 membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms. Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl), and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azacycloheptatrienyl, oxacycloheptatrienyl, and thiacycloheptatrienyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothienyl, isobenzothienyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indazinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolyl, isoquinolyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. The heteroaryl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0052] Specific examples of preferred heteroaryl groups include: pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, pyranyl, 2-furanyl, 3-furan, 2-thienyl, 3-thienyl, oxazolyl, isoxazolyl, oxazolyl (1,2,4-oxazolyl, 1,3,4-oxazolyl, 1,2,5-oxazolyl, thiazolyl, thiadiazolyl (1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl).

[0053] "Carbonyl" whether used alone or in combination with other terms (eg, aminocarbonyl) is represented by -C(O)-.

[0054] "Oxo" means =0.

[0055] "Thio" means =S.

[0056] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl groups and the like as defined herein are optionally substituted groups.

[0057] Exemplary substituents on carbon atoms include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa 、-ON(R bb )2、-N(R bb )2、-N(R bb )3 + X - 、-N(OR cc )R bb , -SH, -SR aa 、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc 2. -CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2, -OC(=O)N(R bb )2.-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2, -C(=NR bb )R aa 、-C(=NR bb )ORaa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3、-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa )2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)2N(R bb )2、-OP(=O)2N(R bb )2、-P(=O)(NR bb )2、-OP(=O)(NR bb )2、-NR bb P(=O)(OR cc )2、-NR bb P(=O)(NR bb )2、-P(R cc )2、-P(R cc )3、-OP(Rcc )2.-OP(R cc )3. -B(R aa )2、-B(OR cc )2. -BR aa (OR cc ), alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0058] Or the two geminal hydrogen atoms on the carbon atom are replaced by groups =O, =S, =NN (R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O)2R aa , =NR bb or = NOR cc replace;

[0059] R aa Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, or two R aa The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;

[0060] R bb Each of is independently selected from: hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc、-P(=O)2R aa 、-P(=O)(R aa )2、-P(=O)2N(R cc )2, -P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl and heteroaryl, or two R bb The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;

[0061] R cc Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, or two R cc The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;

[0062] R dd Each of is independently selected from: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee 、-ON(R ff )2、-N(R ff )2,-N(R ff )3 + X - 、-N(OR ee )R ff , -SH, -SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC(=O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2, -OC(=O)N(R ff )2.-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2, -C(=NR ff )OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff)OR ee 、-C(=NR ff )N(R ff )2, -OC(=NR ff )N(R ff )2.-NR ff C(=NR ff )N(R ff )2.-NR ff S02R ee 、-SO2N(R ff 2. -SO2R ee 、-SO2OR ee 、-OSO2R ee 、-S(=O)R ee 、-Si(R ee )3.-OSi(R ee )3. -C(=S)N(R ff )2, -C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)2R ee 、-P(=O)(R ee )2.-OP(=O)(R ee )2.-OP(=O)(OR ee )2, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution, or two geminal R dd Substituents may combine to form =O or =S;

[0063] R ee Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution;

[0064] R ff Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, or two R ff The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution;

[0065] R ggEach of is independently: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - 、-NH(C 1-6 Alkyl)2 + X - 、-NH2(C 1-6 alkyl) + X - 、-NH3 + X - 、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6 Alkyl)2, -SO2NH(C 1-6 Alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 Alkyl)3, -OSi(C 1-6 Alkyl)3, -C(=S)N(C 1-6 alkyl)2, C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 Alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)2(C 1-6 alkyl), -P(=O)(C 1-6 Alkyl)2, -OP(=O)(C 1-6 Alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 carbocyclic group, C6-C 10 Aryl, C3-C7 heterocyclic, C5-C 10 heteroaryl; or two geminal R gg Substituents may combine to form =O or =S; wherein X - For the counter ion.

[0066] Exemplary substituents on nitrogen atoms include, but are not limited to, hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR bb )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SORaa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa ,-P(=O)(R aa )2、-P(=O)2N(R cc )2, -P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, or two R attached to the nitrogen atom cc The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd substituted with a group, and wherein R aa , R bb , R cc and R dd As mentioned above.

[0067] Other definitions

[0068] The term "cancer" includes, but is not limited to, the following cancers: cancers of the breast, ovary, cervix, prostate, testicle, esophagus, stomach, skin, lung, bone, colon, pancreas, thyroid, bile duct, buccal cavity and pharynx (mouth), lip, tongue, oral cavity, pharynx, small intestine, colorectal, large intestine, rectum, brain and central nervous system, glioblastoma, neuroblastoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, adenocarcinoma, adenoma, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder cancer, liver cancer, kidney cancer, bone marrow disorders, lymphatic disorders, Hodgkin's disease, hairy cell cancer, and leukemia.

[0069] The term "treat" as used herein relates to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which the term applies, or one or more symptoms of such a disorder or condition. The noun "treat" as used herein relates to the action of the verb treat, the latter being as just defined.

[0070] The term "pharmaceutically acceptable salt" as used herein refers to those carboxylates, amino acid addition salts of the compounds of the present invention which are suitable for use in contact with patient tissues within the scope of sound medical judgment, do not produce undue toxicity, irritation, allergic response, etc., are commensurate with a reasonable benefit / risk ratio, and are effective for their intended use, including (where possible) zwitterionic forms of the compounds of the present invention.

[0071] Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali metals and alkaline earth metal hydroxides or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, etc. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine.

[0072] Base addition salts of acidic compounds may be prepared by contacting the free acid form with a sufficient amount of the desired base to form the salt in a conventional manner. The free acid may be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but for purposes of the present invention, the salts are equivalent to their respective free acids.

[0073] Salts can be sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides prepared from inorganic acids, such as hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, etc. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, methanesulfonate, glucoheptonate, lactobionate, laurylsulfonate and isethionate, etc. Salts can also be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Representative salts include acetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, naphthoate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, etc. Pharmaceutically acceptable salts may include cations based on alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, etc., as well as non-toxic ammonium, quaternary ammonium, and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. Also contemplated are salts of amino acids, such as argininate, gluconate, galacturonate, and the like (see, e.g., Berge SM et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977; 66: 1-19, incorporated herein by reference).

[0074] Examples of pharmaceutically acceptable non-toxic amides of the compounds of the present invention includel -C6 alkyl esters, wherein the alkyl group is straight chain or branched. Acceptable esters also include C5-C7 cycloalkyl esters and aryl alkyl esters, such as but not limited to benzyl esters. C1-C4 alkyl esters are preferred. Esters of the compounds of the present invention can be prepared according to conventional methods, for example: March's Advanced Organic Chemistry, 5 Edition "MB Smith & J. March, John Wiley & Sons, 2001.

[0075] Examples of pharmaceutically acceptable non-toxic amides of the compounds of the present invention include amides derived from ammonia, primary C1-C6 alkylamines and secondary C1-C6 dialkylamines, wherein the alkyl group is straight chain or branched. In the case of secondary amines, the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C1-C3 alkyl primary amines and C1-C2 dialkyl secondary amines are preferred. Amides of the compounds of the present invention may be prepared according to conventional methods, for example: March's Advanced Organic Chemistry, 5 Edition", MB Smith & J. March, John Wiley & Sons, 2001.

[0076] "Subjects" for administration include, but are not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.

[0077] "Disease," "disorder," and "condition" are used interchangeably herein.

[0078] As used herein, and unless otherwise indicated, the terms "treatment," "treating," "treating," "treating," and "treatment" include actions that occur while a subject has a particular disease, disorder, or condition, that reduce the severity of, or delay or slow the development of, the disease, disorder, or condition ("therapeutic treatment"), and also include actions that occur before a subject develops a particular disease, disorder, or condition ("prophylactic treatment").

[0079] Generally, the "effective amount" of a compound refers to an amount sufficient to cause a target biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of the compounds of the invention may vary depending on factors such as the biological target, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and symptoms of the subject. An effective amount includes a therapeutically effective amount and a prophylactically effective amount.

[0080] Unless otherwise specified, a "therapeutically effective amount" of a compound as used herein is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" can include an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic effect of other therapeutic agents.

[0081] Unless otherwise specified, a "prophylactically effective amount" of a compound as used herein is an amount sufficient to prevent a disease, disorder, or condition, or an amount sufficient to prevent one or more symptoms associated with a disease, disorder, or condition, or an amount to prevent the recurrence of a disease, disorder, or condition. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent that provides a prophylactic benefit in the process of preventing a disease, disorder, or condition when used alone or in combination with other agents. The term "prophylactically effective amount" may include an amount that improves overall prevention, or an amount that enhances the prophylactic effect of other prophylactic agents.

[0082] "Combination" and related terms refer to the simultaneous or sequential administration of the compounds of the invention and other therapeutic agents. For example, the compounds of the invention can be administered simultaneously or sequentially with the other therapeutic agents in separate unit dosage forms, or can be administered simultaneously with the other therapeutic agents in a single unit dosage form. Specific implementation plan

[0083] As used herein, "compounds of the present invention" refers to compounds of the following formula (I) to formula (VI) (including sub-general formulae), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof.

[0084] Herein, compounds are named using standard nomenclature. For compounds having asymmetric centers, it should be understood that (unless otherwise specified) all optical isomers and mixtures thereof are included. In addition, unless otherwise specified, all isomeric compounds included in the present invention may appear in the Z and E forms with carbon-carbon double bonds. Compounds that exist in different tautomeric forms, a compound is not limited to any particular tautomer, but is intended to cover all tautomeric forms. General formulas used for certain compounds, including descriptions, variables. Unless otherwise specified, each variable in such a formula is defined independently of any other variable and any variable in a formula is defined independently at each occurrence of multiple variables.

[0085] In one embodiment, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and mixtures thereof:

[0086]

[0087] in,

[0088] X is CR X or N;

[0089] Y is CR Y or N;

[0090] R1, R2, R3, R4 and R Y are independently selected from H, D, halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R1 and R2, R3 and R4 are connected to form a bond, C 1-6 Alkylene, C 2-6 Alkenylene or C 2-6 Alkyne; wherein the group may be substituted by one or more D or halogen until fully substituted;

[0091] Where R X is H, D, halogen, -CN, -NRR', -OR, -SR or C 1-6 Alkyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0092] When Y is CR Y When R Y , R1 together with the atoms to which they are attached form C 3-5 Cycloalkyl or 3-5 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0093] Ring A is phenyl or a 5-6 membered heteroaryl group;

[0094] R a independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 3-8 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0095] m = 0, 1, 2, 3, 4 or 5;

[0096] Ring B is a 5-10 membered heteroaryl group;

[0097] R b independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 3-8 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0098] n=0, 1, 2, 3, 4 or 5;

[0099] R5 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0100] R6 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0101] R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 3-7 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0102] R and R' are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein said group may be substituted by one or more D or halogen until fully substituted;

[0103] p=1 or 2.

[0104] X and Y

[0105] In one embodiment, X is CR X In another specific embodiment, X is CH; In another specific embodiment, X is N.

[0106] In a specific embodiment, Y is CR Y In another specific embodiment, Y is N.

[0107] R1, R2, R3, R4 and R Y

[0108] In one embodiment, R1 is H; in another embodiment, R1 is D; in another embodiment, R1 is halogen; in another embodiment, R1 is C 1-6 Alkyl, such as (R)-C 1-6 Alkyl, such as (R)-methyl; in another embodiment, R1 is C 1-6 Haloalkyl, such as (R)-C 1-6 In another embodiment, R1 is C 2-6 In another embodiment, R1 is C 2-6 Alkynyl.

[0109] In one embodiment, R2 is H; in another embodiment, R2 is D; in another embodiment, R2 is halogen; in another embodiment, R2 is C 1-6 Alkyl, such as (R)-C 1-6Alkyl, such as (R)-methyl; in another embodiment, R2 is C 1-6 Haloalkyl, such as (R)-C 1-6 In another embodiment, R2 is C 2-6 In another embodiment, R2 is C 2-6 Alkynyl.

[0110] In one embodiment, R3 is H; in another embodiment, R3 is D; in another embodiment, R3 is halogen; in another embodiment, R3 is C 1-6 Alkyl, such as (R)-C 1-6 Alkyl, such as (R)-methyl; in another embodiment, R3 is C 1-6 Haloalkyl, such as (R)-C 1-6 In another embodiment, R3 is C 2-6 In another specific embodiment, R3 is C 2-6 Alkynyl.

[0111] In one embodiment, R4 is H; in another embodiment, R4 is D; in another embodiment, R4 is halogen; in another embodiment, R4 is C 1-6 Alkyl, such as (R)-C 1-6 Alkyl, such as (R)-methyl; in another embodiment, R4 is C 1-6 Haloalkyl, such as (R)-C 1-6 In another embodiment, R4 is C 2-6 In another specific embodiment, R4 is C 2-6 Alkynyl.

[0112] In a specific embodiment, R Y is H; in another specific embodiment, R Y is D; in another specific embodiment, R Y is halogen; in another specific embodiment, R Y C 1-6 Alkyl, such as (R)-C 1-6 Alkyl, such as (R)-methyl; in another embodiment, R Y C 1-6 Haloalkyl, such as (R)-C 1-6 haloalkyl; in another specific embodiment, R Y C 2-6 alkenyl; in another specific embodiment, R Y C2-6 Alkynyl.

[0113] In another specific embodiment, at least one of R1 and R2 is C 1-6 Alkyl, such as (R)-C 1-6 Alkyl, for example (R)-methyl.

[0114] In another embodiment, R1 and R2, or R3 and R4 are connected to form a bond; in another embodiment, R1 and R2, or R3 and R4 are connected to form a C 1-6 Alkylene, such as methylene, ethylene or propylene; in another specific embodiment, R1 and R2, or R3 and R4 are connected to form a C 2-6 In another embodiment, R1 and R2, or R3 and R4 are connected to form C 2-6 Alkyne group.

[0115] In another embodiment, the above groups may be substituted with one or more D or halogen, up to full substitution.

[0116] In another specific embodiment, when Y is CR Y When R Y , R1 together with the atoms to which they are attached form C 3-5 Cycloalkyl; In another specific embodiment, the C 3-5 Cycloalkyl is cyclopropyl; in another specific embodiment, the C 3-5 Cycloalkyl is cyclobutyl; in another specific embodiment, the C 3-5 Cycloalkyl is cyclopentyl; in another embodiment, when Y is CR Y When R Y , R1 together with the atoms to which they are attached form a 3-5 membered heterocyclic group; in another specific embodiment, the 3-5 membered heterocyclic group is oxetanyl, aziridine or thiirane; in another specific embodiment, the 3-5 membered heterocyclic group is oxetanyl, azetidinyl or thiirane; in another specific embodiment, the 3-5 membered heterocyclic group is tetrahydrofuranyl, pyrrolidinyl or thiolyl. In another specific embodiment, the C 3-5 The 3- to 5-membered cycloalkanes and the 3- to 5-membered heterocyclic groups may be substituted by one or more D or halogens until fully substituted;

[0117] Ring A

[0118] In one specific embodiment, ring A is phenyl; in another specific embodiment, ring A is 5-6 membered heteroaryl.

[0119] In another specific embodiment, Ring A is selected from Among them, A1 is CR a1 or N; A2 is CR a2 or N; A3 is CR a3 or N; A4 is CR a4 or N; A5 is CR a5 or N; R a1 , R a2 , R a3 , R a4 and R a5 As mentioned above for R a In another specific embodiment, ring A is selected from

[0120] R a

[0121] In a specific embodiment, R a independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 3-8 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted; in another specific embodiment, one of R a is H; in another specific embodiment, one R a is D; in another specific embodiment, one R a is halogen; in another specific embodiment, one R a is -CN; in another specific embodiment, one R a is -NRR'; in another specific embodiment, one R a is -OR; in another specific embodiment, one of the R a is -SR; in another specific embodiment, one R a is -C(O)R; in another specific embodiment, one R a is -C(O)OR; in another specific embodiment, one R a is -C(O)NRR'; in another specific embodiment, one R a is -OC(O)R'; in another specific embodiment, one R ais -NRC(O)R'; in another specific embodiment, one R a is -OC(O)NRR'; in another specific embodiment, one R a is -NRC(O)NRR'; in another specific embodiment, one R a -S(O) p R; In another specific embodiment, one R a C 1-6 Alkyl; In another specific embodiment, one R a C 2-6 alkenyl; in another specific embodiment, one R a C 2-6 Alkynyl; In another specific embodiment, one R a C 3-7 Cycloalkyl; In another specific embodiment, one R a is a 3-8 membered heterocyclyl; in another specific embodiment, one of R a is substituted with one, two or three R*; in another specific embodiment, wherein said group may be substituted with one or more D or halogen, up to full substitution.

[0122] In another specific embodiment, R a independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D up to full deuteration.

[0123] m

[0124] In one embodiment, m=0; in another embodiment, m=1; in another embodiment, m=2; in another embodiment, m=3; in another embodiment, m=4; in another embodiment, m=5.

[0125] Ring B

[0126] In one embodiment, ring B is a 5-10 membered heteroaryl, such as a bicyclic 9-10 membered heteroaryl; in another embodiment, ring B is Among them, B1-B 12 0, 1, 2 or 3 of them are heteroatoms selected from O, S and N, as long as chemically permitted; and B1-B 12Optionally oxidized to form a =O group; preferably, B1-B 12 At least one of them is a heteroatom selected from O, S and N, as long as it is chemically permitted;

[0127] Preferably, B1-B 12 There are 0, 1, 2 or 3 N atoms in B1-B 12 Preferably, at least one of B1-B3 is a N atom; preferably, B1-B3 contain at most one N atom; preferably, B4-B6 contain at most two N atoms; preferably, B4 is a N atom.

[0128] In another specific embodiment, Ring B is selected from in,

[0129] B1 is CR b1 or N; B2 is CR b2 or N; B3 is CR b3 or N; B4 is CR b4 or N; B5 is CR b5 or N; B6 is CR b6 or N; B7 is CR b7 or N; B8 is CR b8 or N; B9 is CR b9 or N; B 10 CR b10 or N; B 11 CR b11 or N; B 12 CR b12 or N;

[0130] R b1 To R b12 and R b With the above for R b defined;

[0131] n = 0, 1, 2, 3 or 4;

[0132] R7 and R8 are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0133] Wherein R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 3-7Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0134] r = 0, 1, 2, 3, 4 or 5;

[0135] Alternatively, R7, R8 and the N atom to which they are attached together form a 4-8 membered heterocyclic group, which may be substituted by one or more D or halogen until fully substituted;

[0136] R and R' are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein said group may be substituted by one or more D or halogen until fully substituted;

[0137] p=1 or 2.

[0138] In another specific embodiment, Ring B is selected from Preferably, ring B is selected from In another specific embodiment, Ring B is In another specific embodiment, Ring B is In another specific embodiment, Ring B is

[0139] R b

[0140] In a specific embodiment, R b independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 3-8 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted; in another specific embodiment, one of R b is H; in another specific embodiment, one R b is D; in another specific embodiment, one R b is halogen; in another specific embodiment, one R bis -CN; in another specific embodiment, one R b is -NRR'; in another specific embodiment, one R b is -OR; in another specific embodiment, one of the R b is -SR; in another specific embodiment, one R b is -C(O)R; in another specific embodiment, one R b is -C(O)OR; in another specific embodiment, one R b is -C(O)NRR'; in another specific embodiment, one R b is -OC(O)R'; in another specific embodiment, one R b is -NRC(O)R'; in another specific embodiment, one R b is -OC(O)NRR'; in another specific embodiment, one R b is -NRC(O)NRR'; in another specific embodiment, one R b -S(O) p R; In another specific embodiment, one R b C 1-6 Alkyl; In another specific embodiment, one R b C 2-6 alkenyl; in another specific embodiment, one R b C 2-6 Alkynyl; In another specific embodiment, one R b C 3-7 Cycloalkyl; In another specific embodiment, one R b is a 3-8 membered heterocyclyl; in another specific embodiment, one of R b is substituted with one, two or three R*; in another specific embodiment, wherein said group may be substituted with one or more D or halogen, up to full substitution.

[0141] In another specific embodiment, R b independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl or C 1-6 Halogenated alkyl.

[0142] n

[0143] In one embodiment, n=0; in another embodiment, n=1; in another embodiment, n=2; in another embodiment, n=3; in another embodiment, n=4; in another embodiment, n=5.

[0144] R5

[0145] In one embodiment, R5 is H; in another embodiment, R5 is D; in another embodiment, R5 is halogen; in another embodiment, R5 is -CN; in another embodiment, R5 is -NRR'; in another embodiment, R5 is -OR; in another embodiment, R5 is -SR; in another embodiment, R5 is C 1-6 In another embodiment, R5 is C 2-6 In another specific embodiment, R5 is C 2-6 Alkynyl; In another embodiment, R5 can be substituted with one or more D or halogen, up to full substitution.

[0146] R6

[0147] In one embodiment, R6 is H; in another embodiment, R6 is D; in another embodiment, R6 is halogen; in another embodiment, R6 is -CN; in another embodiment, R6 is -NRR'; in another embodiment, R6 is -OR; in another embodiment, R6 is -SR; in another embodiment, R6 is C 1-6 Alkyl; in another specific embodiment, R6 is C 2-6 In another embodiment, R6 is C 2-6 Alkynyl; In another embodiment, R6 can be substituted with one or more D or halogen, up to full substitution.

[0148] R*

[0149] In one embodiment, R* is H; in another embodiment, R* is halogen; in another embodiment, R* is -CN; in another embodiment, R* is -NRR'; in another embodiment, R* is -OR; in another embodiment, R* is -SR; in another embodiment, R* is -C(O)R; in another embodiment, R* is -C(O)OR; in another embodiment, R* is -C(O)NRR'; in another embodiment, R* is -OC(O)R'; in another embodiment, R* is -NRC(O)R'; in another embodiment, R* is -OC(O)NRR'; in another embodiment, R* is -NRC(O)NRR'; in another embodiment, R* is -S(O) p R; In another specific embodiment, R* is C 3-7 Cycloalkyl; in another specific embodiment, R* is 3-8 membered heterocyclyl; in another specific embodiment, R* is C 6-10 Aryl; in another embodiment, R* is a 5-10 membered heteroaryl; in another embodiment, R* may be substituted with one or more D or halogen until fully substituted.

[0150] R and R'

[0151] In one embodiment, R and R' are independently H; in another embodiment, R and R' are independently C 1-6 In another embodiment, R and R' are independently C 2-6 In another embodiment, R and R' are independently C 2-6 Alkynyl; in another embodiment, R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; in another embodiment, R and R' may be substituted by one or more D or halogen, until fully substituted.

[0152] p

[0153] In one embodiment, p=1; in another embodiment, p=2.

[0154] Any technical solution or any combination thereof in any of the above specific embodiments can be combined with any technical solution or any combination thereof in other specific embodiments. For example, any technical solution or any combination thereof of X can be combined with Y, R1-R6, ring A, ring B, R a , R bThe present invention is intended to include combinations of all these technical solutions, which are not listed one by one due to space limitations.

[0155] In a more specific embodiment, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, which has the following general structure:

[0156]

[0157] wherein each group is as defined above and below.

[0158] In a more specific embodiment, the present invention provides a compound of formula (V-1) or (VI-1), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof:

[0159]

[0160] in,

[0161] A1 is CR a1 or N;

[0162] A2 is CR a2 or N;

[0163] A3 is CR a3 or N;

[0164] A4 to CR a4 or N;

[0165] A5 is CR a5 or N;

[0166] R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6Cycloalkyl or 3-6 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0167] R b independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0168] n = 0, 1, 2, 3 or 4;

[0169] R1 is H, D, halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0170] R5 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0171] R6 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0172] R7 and R8 are independently H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0173] R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 3-7 Cycloalkyl, 3-8 membered heterocyclic group, C6-10 Aryl or 5-10 membered heteroaryl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0174] r = 0, 1, 2, 3, 4 or 5;

[0175] Alternatively, R7, R8 and the N atom to which they are attached together form a 4-8 membered heterocyclic group, which may be substituted by one or more D or halogen until fully substituted;

[0176] R and R' are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein said group may be substituted by one or more D or halogen until fully substituted;

[0177] p=1 or 2.

[0178] In a more specific embodiment, the present invention provides the above-mentioned compound, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein R a1 , R a2 , R a3 , R a4 and R a5 are independently H, D, halogen, -CN, -C(O)OR, -C(O)NRR', -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, which may be substituted by one or more D or halogen, up to full substitution.

[0179] In a more specific embodiment, the present invention provides a compound of formula (V-1) or (VI-1), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein:

[0180] A1 is CR a1 ;

[0181] A2 is CR a2 or N;

[0182] A3 is CR a3 or N;

[0183] A4 to CR a4 or N;

[0184] A5 is CRa5 ;

[0185] R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -C(O)OR, -C(O)NRR', -NRR' or -OH optionally substituted with R*;

[0186] R b is H, D, halogen, -CN, -NRR', -OR or -SR;

[0187] n = 0, 1, 2, 3 or 4;

[0188] R1 is H, D, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0189] R5 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0190] R6 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0191] R7 and R8 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0192] R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 3-7Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, wherein said group may be substituted by one or more D until fully deuterated;

[0193] r = 0, 1, 2, 3, 4 or 5;

[0194] Alternatively, R7, R8 and the N atom to which they are attached together form a 4-8 membered heterocyclic group, which may be substituted by one or more D until fully deuterated;

[0195] R and R' are independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein said group may be substituted by one or more D until fully deuterated;

[0196] p=1 or 2.

[0197] In a more specific embodiment, the present invention provides the above-mentioned compound, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein:

[0198] R a1 , R a4 and R a5 independently H or D;

[0199] R a2 and R a3 are independently H, D, halogen, -CN, -C(O)OR, -C(O)NRR', -NRR' or -OH;

[0200] R1 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0201] R5 is H, D, halogen, -CN, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0202] R6 is H, D, halogen, -CN, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0203] R7 and R8 are independently H, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0204] R* is H, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR' or -NRC(O)NRR';

[0205] r = 0, 1, 2, 3, 4 or 5;

[0206] Alternatively, R7, R8 and the N atom to which they are attached together form a 4-8 membered heterocyclic group, which may be substituted by one or more D until fully deuterated;

[0207] R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 The haloalkyl group, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein the group may be substituted by one or more D until fully deuterated.

[0208] In a more specific embodiment, the present invention provides a compound of formula (V-1) or (VI-1), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein:

[0209] A1 is CR a1 ;

[0210] A2 is CR a2 ;

[0211] A3 is CR a3 or N;

[0212] A4 to CR a4 or N;

[0213] A5 is CR a5 ;

[0214] R a1 , R a2 , R a3 , R a4 and R a5 are independently H, D, halogen, -C(O)OH, -C(O)NH2 or -OH;

[0215] R b is H, D, halogen or -CN;

[0216] n = 0, 1, 2, 3 or 4;

[0217] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0218] R5 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0219] R6 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0220] R7 and R8 are independently H, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0221] R* is H, halogen, -CN, -NRR' or -OR;

[0222] r = 0, 1, 2, 3, 4 or 5;

[0223] Or, R7, R8 and the N atom to which they are attached together form a 4-8 membered heterocyclic group;

[0224] R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group, wherein the group may be substituted by one or more Ds until fully deuterated.

[0225] In a more specific embodiment, the present invention provides the above-mentioned compound, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein R a1 , R a4 and R a5 is H or D;

[0226] R a2 and R a3 is H, D, halogen, -C(O)NH2 or -OH;

[0227] R1 is C 1-6 Alkyl or C 1-6 Halogenated alkyl; preferably methyl;

[0228] R5 is C1-6 Alkyl or C 1-6 Haloalkyl; preferably methyl or -CF3;

[0229] R6 is C 1-6 Alkyl or C 1-6 Haloalkyl; preferably methyl or -CF3;

[0230] R7 and R8 are independently H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0231] R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 The halogenated alkyl group or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group.

[0232] In a more specific embodiment, the present invention provides a compound of formula (V-2), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof:

[0233]

[0234] in,

[0235] A1 is CR a1 or N;

[0236] A2 is CR a2 ;

[0237] A3 is CR a3 or N;

[0238] A4 is N;

[0239] A5 is CR a5 or N;

[0240] B2 is CR b2 ;

[0241] B3 is CR b3 ;

[0242] R a1 , R a2 , R a3 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0243] R b2 and R b3 independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0244] R b Selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl or 3-8 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0245] n = 0, 1, 2, 3 or 4;

[0246] R1 is H, D, halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0247] R5 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0248] R6 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0249] R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 3-7 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0250] R and R' are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein said group may be substituted by one or more D or halogen until fully substituted;

[0251] p=1 or 2.

[0252] In a more specific embodiment, the present invention provides a compound of formula (V-2), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein:

[0253] A1 is CR a1 or N;

[0254] A2 is CR a2 ;

[0255] A3 is CR a3 or N;

[0256] A4 is N;

[0257] A5 is CR a5 or N;

[0258] B2 is CR b2 ;

[0259] B3 is CR b3 ;

[0260] R a1 , R a2 , R a3 and R a5independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0261] R b2 and R b3 independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0262] R b is selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0263] n = 0, 1, 2, 3 or 4;

[0264] R1 is halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0265] R5 is halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0266] R6 is halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0267] R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 3-7 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0268] R and R' are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein said group may be substituted by one or more D or halogen until fully substituted;

[0269] p=1 or 2.

[0270] In a more specific embodiment, the present invention provides a compound of formula (V-2), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein:

[0271] A1 is CR a1 or N;

[0272] A2 is CR a2 ;

[0273] A3 is CR a3 or N;

[0274] A4 is N;

[0275] A5 is CR a5 or N;

[0276] B2 is CR b2 ;

[0277] B3 is CR b3 ;

[0278] R a1 is H, D, halogen or -CN;

[0279] R a2 is selected from H, D, halogen, -NRR', -OR, -SR, -C(O)R, -C(O)OR or -C(O)NRR' optionally substituted by R*, wherein said groups may be substituted by one or more D up to full deuteration;

[0280] R a3is selected from H, D, halogen, -CN, -NH2, -OH, -SH, -C(O)R, -C(O)OR or -C(O)NRR', wherein the group may be substituted by one or more D or halogen until fully substituted;

[0281] R a5 is selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0282] R b2 is selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0283] R b3 is selected from H, D, halogen, -CN, -NRR', -OR or -SR optionally substituted by R*, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0284] R b is H, D, halogen or -CN;

[0285] n = 0, 1, 2, 3 or 4;

[0286] R1 is halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0287] R5 is halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0288] R6 is halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0289] R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR or -C(O)NRR', wherein said groups may be substituted by one or more D or halogen until fully substituted;

[0290] R and R' are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein the group may be substituted by one or more D or halogen until fully substituted.

[0291] In a more specific embodiment, the present invention provides a compound of formula (V-2), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein:

[0292] A1 is CR a1 or N;

[0293] A2 is CR a2 ;

[0294] A3 is CR a3 or N;

[0295] A4 is N;

[0296] A5 is CR a5 or N;

[0297] B2 is CR b2 ;

[0298] B3 is CR b3 ;

[0299] R a1 is H or D;

[0300] R a2 is selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR or -C(O)NRR' optionally substituted with R*;

[0301] R a3 is selected from H, D, halogen, -CN, -NRR', -OR, -SR;

[0302] R a5 is selected from H, D, halogen, -CN or C optionally substituted by R* 1-6 alkyl;

[0303] R b2 is selected from H, D, halogen, -CN or C optionally substituted by R* 1-6 alkyl;

[0304] R b3 is selected from H or D optionally substituted with R*;

[0305] R b is H or D;

[0306] n = 0, 1, 2, 3 or 4;

[0307] R1 is C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0308] R5 is C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0309] R6 is C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl;

[0310] R* is H, halogen, -CN, -NRR', -OR or -SR;

[0311] R and R' are independently selected from H or C 1-6 alkyl.

[0312] In a more specific embodiment, the present invention provides a compound of formula (V-2) or (VI-2), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof:

[0313]

[0314] in,

[0315] A1 is CR a1 or N;

[0316] A2 is CR a2 or N;

[0317] A3 is CR a3 or N;

[0318] A4 to CR a4 or N;

[0319] A5 is CR a5 or N;

[0320] B2 is CR b2 or N;

[0321] B3 is CR b3 or N;

[0322] R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclyl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0323] R b2 , R b3 and R b independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) optionally substituted with R* p R, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0324] n = 0, 1, 2, 3 or 4;

[0325] R1 is H, D, halogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0326] R5 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0327] R6 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0328] R* is H, halogen, -CN, -NRR', -OR, -SR, -C(O)R, -C(O)OR, -C(O)NRR', -OC(O)R', -NRC(O)R', -OC(O)NRR', -NRC(O)NRR', -S(O) p R, C 3-7 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, wherein said group may be substituted by one or more D or halogen until fully substituted;

[0329] R and R' are independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein said group may be substituted by one or more D or halogen until fully substituted;

[0330] p=1 or 2.

[0331] In a more specific embodiment, the present invention provides the above-mentioned compound, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein:

[0332] R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, -C(O)OR, -C(O)NRR', C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said group may be substituted by one or more D or halogen, up to complete substitution;

[0333] R b2 , R b3 and R b independently selected from H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D or halogen, up to full substitution.

[0334] In a more specific embodiment, the present invention provides a compound of formula (V-2) or (VI-2), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein:

[0335] A1 is CR a1 or N;

[0336] A2 is CR a2 or N;

[0337] A3 is CR a3 or N;

[0338] A4 to CR a4 or N;

[0339] A5 is CR a5 or N;

[0340] Preferably, at least one of A3, A4 and A5 is N;

[0341] B2 is CR b2 or N;

[0342] B3 is CR b3 or N;

[0343] R a1 , R a2 , R a3 , R a4 and R a5 is H, D, halogen, -CN, -C(O)OR, -C(O)NRR', -NRR' or -OH;

[0344] R b2 , R b3 and R b are independently selected from H, D, halogen, -CN, -NRR', -OR, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0345] n = 0, 1, 2, 3 or 4;

[0346] R1 is H, D, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0347] R5 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0348] R6 is H, D, halogen, -CN, -NRR', -OR, -SR, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0349] R* is H, halogen, -CN, -NRR', -OR or -SR;

[0350] R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 The haloalkyl group, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein the group may be substituted by one or more D until fully deuterated.

[0351] In a more specific embodiment, the present invention provides the above-mentioned compound, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein:

[0352] R b2 , R b3 and R b independently selected from H, D, halogen, -CN, -NRR', -OH, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0353] R1 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0354] R5 is H, D, halogen, -CN, C 1-6 Alkyl or C 1-6Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0355] R6 is H, D, halogen, -CN, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the radical may be substituted by one or more D up to full deuteration.

[0356] In a more specific embodiment, the present invention provides a compound of formula (V-2) or (VI-2), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and a mixture thereof, wherein:

[0357] A1 is CR a1 or N;

[0358] A2 is CR a2 or N;

[0359] A3 is CR a3 or N;

[0360] A4 to CR a4 or N;

[0361] A5 is CR a5 or N;

[0362] Preferably, at least one of A3, A4 and A5 is N;

[0363] B2 is CR b2 or N;

[0364] B3 is CR b3 or N;

[0365] R a1 and R a5 is H or D;

[0366] R a3 is H, D or OH;

[0367] R a2 and R a4 is H, D, halogen, -NRR' or -OH;

[0368] R b2 , R b3 and R b independently selected from H, D, halogen, -CN, -NRR', -OH, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0369] n = 0, 1, 2, 3 or 4;

[0370] R1 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0371] R5 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0372] R6 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein said radical may be substituted by one or more D up to full deuteration;

[0373] R* is H, halogen, -CN, -NRR', -OR or -SR;

[0374] R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 The haloalkyl group, or R, R' and the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; wherein the group may be substituted by one or more D until fully deuterated.

[0375] In a more specific embodiment, the present invention provides the above-mentioned compound, or its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof, wherein R b2 , R b3 and R b are independently selected from H, D, halogen, -CN, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0376] R1 is C 1-6 Alkyl or C 1-6 Halogenated alkyl; preferably methyl;

[0377] R5 is C 1-6 Alkyl or C 1-6 Haloalkyl; preferably methyl or -CF3;

[0378] R6 is C 1-6 Alkyl or C 1-6 Halogenated alkyl; preferably methyl or -CF3.

[0379] Preferred compounds of the present invention include, but are not limited to, the compounds listed below, or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof:

[0380]

[0381]

[0382]

[0383] The compounds of the present invention may include one or more asymmetric centers and may therefore exist in a variety of stereoisomeric forms, for example, enantiomers and / or diastereoisomeric forms. For example, the compounds of the present invention may be individual enantiomers, diastereomers or geometric isomers (e.g., cis and trans isomers), or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.

[0384] Those skilled in the art will appreciate that organic compounds can form complexes with solvents in which they react or from which they precipitate or crystallize. These complexes are referred to as "solvates". When the solvent is water, the complex is referred to as a "hydrate". The present invention encompasses all solvates of the compounds of the present invention.

[0385] The term "solvate" refers to a form of a compound or its salt that is combined with a solvent, usually formed by a solvent decomposition reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, ether, etc. The compounds described herein can be prepared, for example, in a crystalline form and can be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include stoichiometric solvates and non-stoichiometric solvates. In some cases, the solvate will be able to separate, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" includes solvates in solution and separable solvates. Representative solvates include hydrates, ethanolates and methanolates.

[0386] The term "hydrate" refers to a compound that is combined with water. Generally, the ratio of the number of water molecules contained in the hydrate of a compound to the number of molecules of the compound in the hydrate is determined. Therefore, the hydrate of a compound can be represented by, for example, the general formula R·xH2O, where R is the compound, and x is a number greater than 0. A given compound can form more than one type of hydrate, including, for example, a monohydrate (x is 1), a lower hydrate (x is a number greater than 0 and less than 1, for example, a hemihydrate (R·0.5H2O)) and a polyhydrate (x is a number greater than 1, for example, a dihydrate (R·2H2O) and a hexahydrate (R·6H2O)).

[0387] The compounds of the present invention can be in amorphous or crystalline form (polymorph). In addition, the compounds of the present invention can exist in one or more crystalline forms. Therefore, the present invention includes all amorphous or crystalline forms of the compounds of the present invention within its scope. The term "polymorph" refers to the crystalline form (or its salt, hydrate or solvate) of a compound with a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardnesses, crystal shapes, photoelectric properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors can lead to a dominant crystalline form. The various polymorphs of a compound can be prepared by crystallization under different conditions.

[0388] The present invention also includes isotopically labeled compounds which are identical to those described in formula (I) but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number commonly found in nature. Examples of isotopes that can be introduced into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, for example 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds of the present invention containing the above isotopes and / or other isotopes of other atoms, their prodrugs and pharmaceutically acceptable salts of the compounds or prodrugs are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as those in which a radioactive isotope (e.g. 3 H and 14 C) can be used for drug and / or substrate tissue distribution assays. 3 H and carbon-14, i.e.14 C isotopes are particularly preferred because they are easy to prepare and detect. 2 H, because higher metabolic stability can provide therapeutic benefits, such as prolonged half-life in vivo or reduced dosage requirements, and thus may be preferred in some cases. Isotope-labeled compounds of formula (I) of the present invention and their prodrugs can generally be prepared by replacing non-isotope-labeled reagents with readily available isotope-labeled reagents when carrying out the processes disclosed in the following schemes and / or Examples and Preparation Examples.

[0389] In addition, prodrugs are also included in the context of the present invention. The term "prodrug" as used herein refers to a compound that is converted into its active form having a medical effect in vivo by, for example, hydrolysis in the blood. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and D. Fleisher, S. Ramon and H. Barbra "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19 (2) 115-130, each of which is incorporated herein by reference.

[0390] Prodrugs are any covalently bonded compounds of the present invention that release the parent compound in vivo when such prodrugs are administered to a patient. Prodrugs are usually prepared by modifying functional groups, and the modification is carried out in a manner that allows the modification to be cleaved to produce the parent compound by conventional manipulation or in vivo. Prodrugs include, for example, compounds of the present invention in which hydroxyl, amino or sulfhydryl groups are bonded to any group, which can be cleaved to form hydroxyl, amino or sulfhydryl groups when administered to a patient. Therefore, representative examples of prodrugs include, but are not limited to, acetate / amide, formate / amide and benzoate / amide derivatives of hydroxyl, sulfhydryl and amino functional groups of compounds of formula (I). In addition, in the case of carboxylic acid (-COOH), esters such as methyl esters, ethyl esters, etc. can be used. Esters themselves can be active and / or can be hydrolyzed under human body conditions. Suitable pharmaceutically acceptable in vivo hydrolyzable ester groups include those groups that are easily decomposed in the human body to release the parent acid or its salt.

[0391] The present invention also provides a pharmaceutical preparation comprising a therapeutically effective amount of a compound of formula (I) or a therapeutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient thereof. All of these forms belong to the present invention.

[0392] Pharmaceutical compositions, preparations and kits

[0393] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of the present invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a preventive effective amount of a compound of the present invention.

[0394] The pharmaceutically acceptable excipient used in the present invention refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated together. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the composition of the present invention include (but are not limited to) ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin.

[0395] The present invention also includes a kit (e.g., a pharmaceutical package). The kit provided may include a compound of the invention, other therapeutic agents, and a first and second container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispersible package or other suitable container) containing the compound of the invention and other therapeutic agents. In some embodiments, the kit provided may also optionally include a third container containing a pharmaceutical excipient for diluting or suspending the compound of the invention and / or other therapeutic agents. In some embodiments, the compound of the invention and other therapeutic agents provided in the first container and the second container are combined to form a unit dosage form.

[0396] Drug administration

[0397] Pharmaceutical composition provided by the invention can be administered by many ways, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration, rectal administration, nasal administration, oral administration, vaginal administration, administration by implant or other modes of administration. For example, parenteral administration used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial cavity administration, intrasternal administration, intrathecal administration, intralesional administration and intracranial injection or infusion technology.

[0398] Generally, an effective amount of the compounds provided herein is administered. The amount of the compound actually administered can be determined by a physician according to the relevant circumstances, including the condition being treated, the route of administration selected, the compound actually administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.

[0399] When used to prevent the conditions described herein, the compounds provided herein are administered to a subject at risk of developing the condition, typically based on the advice of a physician and under the supervision of a physician, at dosage levels as described above. Subjects at risk of developing a specific condition typically include those with a family history of the condition, or those identified by genetic testing or screening as being particularly susceptible to developing the condition.

[0400] The pharmaceutical compositions provided herein can also be administered over a long period of time ("chronic administration"). Chronic administration refers to administration of a compound or a pharmaceutical composition thereof over a long period of time, e.g., 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or administration may continue indefinitely, e.g., for the rest of the subject's life. In some embodiments, chronic administration is intended to provide a constant level of the compound in the blood over a long period of time, e.g., within a therapeutic window.

[0401] Various methods of administration can be used to further deliver the pharmaceutical composition of the present invention. For example, in some embodiments, the pharmaceutical composition can be administered by push injection, for example, in order to increase the concentration of the compound in the blood to an effective level. The push dose depends on the target systemic level of the active component through the body, for example, the intramuscular or subcutaneous push dose slowly releases the active component, and the push delivered directly to the vein (for example, by IV intravenous drip) can be delivered more quickly, so that the concentration of the active component in the blood is quickly increased to an effective level. In other embodiments, the pharmaceutical composition can be given in a continuous infusion form, for example, by IV intravenous drip, so as to provide a steady-state concentration of the active component in the subject's body. In addition, in other embodiments, the pharmaceutical composition of the push dose can be first given, and then continuous infusion.

[0402] Oral compositions can be in the form of bulk liquid solutions or suspensions or bulk powders. However, more generally, in order to facilitate accurate dosing, the composition is provided in unit dosage form. The term "unit dosage form" refers to a physical discrete unit suitable as a unit dose for human patients and other mammals, each unit containing a predetermined amount of active substances suitable for producing the desired therapeutic effect and a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or pills, tablets, capsules, etc. in the case of solid compositions. In such compositions, the compound is usually a relatively small component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), and the remainder is various carriers or excipients and processing aids useful for forming the desired administration form.

[0403] For oral dosage, a representative regimen is one to five oral doses per day, especially two to four oral doses, typically three oral doses. Using these dosage modes, each dose provides about 0.01 to about 20 mg / kg of the compound of the invention, and preferred doses each provide about 0.1 to about 10 mg / kg, especially about 1 to about 5 mg / kg.

[0404] In order to provide blood levels similar to those using an injectable dose, or lower blood levels than using an injectable dose, a transdermal dose is generally selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight.

[0405] From about 1 to about 120 hours, especially 24 to 96 hours, the injected dosage level is in the range of about 0.1 mg / kg / hour to at least 10 mg / kg / hour. In order to obtain sufficient steady state levels, a preload bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be given. For a 40 to 80 kg human patient, the maximum total dose cannot exceed about 2 g / day.

[0406] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous carrier and buffers, suspending and dispersing agents, colorants, flavoring agents, etc. Solid forms may include, for example, any of the following components, or compounds of a similar nature: binders, such as microcrystalline cellulose, tragacanth, or gelatin; excipients, such as starch or lactose, disintegrants, such as alginic acid, Primogel, or corn starch; lubricants, such as magnesium stearate; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; or flavoring agents, such as peppermint, methyl salicylate, or orange flavoring.

[0407] Injectable compositions are typically based on injectable sterile saline or phosphate buffered saline, or other injectable excipients known in the art. As previously mentioned, in such compositions, the active compound is typically a minor component, often about 0.05 to 10% by weight, and the remainder is an injectable excipient, etc.

[0408] Typically, transdermal compositions are formulated as topical ointments or creams containing active ingredients. When formulated as an ointment, the active ingredient is typically combined with a paraffin or water-miscible ointment base. Alternatively, the active ingredient can be formulated as an ointment together with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include other components for enhancing the stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and components are included within the scope provided by the invention.

[0409] The compounds of the invention may also be administered by transdermal means. Thus, transdermal administration may be achieved using patches of the reservoir or porous membrane type, or a variety of solid matrices.

[0410] The above components for oral administration, injection or topical administration are representative only. Other materials and processing techniques are described in Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, Part 8, which is incorporated herein by reference.

[0411] The compounds of the invention may also be administered in sustained release form or from a sustained release delivery system. Descriptions of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0412] The present invention also relates to pharmaceutically acceptable formulations of the compounds of the present invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β- and γ-cyclodextrins consisting of 6, 7 and 8 α-1,4-linked glucose units, respectively, which optionally include one or more substituents on the linked sugar moiety, including but not limited to: methylated, hydroxyalkylated, acylated and sulfoalkyl ether substitutions. In some embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, for example, sulfobutyl ether β-cyclodextrin, also known as Captisol. See, for example, US5,376,645. In some embodiments, the formulation includes hexapropyl-β-cyclodextrin (e.g., in water, 10-50%).

[0413] treat

[0414] As described herein, ATR kinase is known to play a role in tumorigenesis and a number of other diseases. We have found that compounds of formula (I) possess potent anti-tumor activity which is believed to be achieved through inhibition of ATR kinase.

[0415] Thus, the compounds of the present invention have value as anti-tumor agents. In particular, the compounds of the present invention have value as anti-proliferative, apoptotic and / or anti-invasive agents in the containment and / or treatment of solid and / or liquid tumor diseases. In particular, the compounds of the present invention are expected to be useful for preventing or treating those tumors that are sensitive to inhibition of ATR. In addition, the compounds of the present invention are expected to be useful for preventing or treating those tumors that are mediated alone or in part by ATR. Therefore, the compounds can be used to produce ATR enzyme inhibition in warm-blooded animals in need of such treatment.

[0416] As described herein, inhibitors of ATR kinase should be of therapeutic value in the treatment of proliferative diseases such as cancer, especially solid tumors such as carcinomas and sarcomas, and leukemias and lymphomas, especially for the treatment of, for example, breast cancer, colorectal cancer, lung cancer (including small cell lung cancer, non-small cell lung cancer and bronchioloalveolar carcinoma) and prostate cancer, and bile duct cancer, bone cancer, bladder cancer, head and neck cancer, kidney cancer, liver cancer, gastrointestinal tissue cancer, esophageal cancer, ovarian cancer, pancreatic cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, cervical cancer and vulvar cancer, as well as leukemias [including acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML)], multiple myeloma and lymphomas.

[0417] Anti-cancer effects useful for treating cancer in patients include, but are not limited to, anti-tumor effects, response rates, time to disease progression, and survival rates. Anti-tumor effects of the treatment methods of the present invention include, but are not limited to, inhibition of tumor growth, delay of tumor growth, regression of tumors, shrinkage of tumors, extension of the time of tumor regrowth after treatment has ceased, and slowing of disease progression. Anti-cancer effects include preventive treatment as well as treatment of existing disease.

[0418] ATR kinase inhibitors or pharmaceutically acceptable salts thereof are also useful in treating cancer patients, including but not limited to blood cancers, such as leukemia, multiple myeloma; lymphomas, such as Hodgkin's disease, non-Hodgkin's lymphoma (including mantle cell lymphoma) and myelodysplastic syndrome, as well as solid tumors and their metastases, such as breast cancer, lung cancer (non-small cell lung cancer (NSCL), small cell lung cancer (SCLC), squamous cell carcinoma), endometrial cancer, central nervous system tumors (such as glioma, embryonic dysplastic neuroepithelial tumor, multiforme glioblastoma, mixed glioma, medulloblastoma, retinal tumors); omentoma, neuroblastoma, germ cell tumor and teratoma, gastrointestinal cancer (such as gastric cancer), esophageal cancer, hepatocellular (liver) cancer, bile duct cancer, colon and rectal cancer, small intestine cancer, pancreatic cancer, skin cancer such as melanoma (especially metastatic melanoma), thyroid cancer, head and neck cancer and salivary gland cancer, prostate cancer, testicular cancer, ovarian cancer, cervical cancer, uterine cancer, vulvar cancer, bladder cancer, kidney cancer (including renal cell carcinoma, clear cell and renal oncocytoma), squamous cell carcinoma, sarcomas such as osteosarcoma, chondrosarcoma, leiomyosarcoma, soft tissue sarcoma, Ewing sarcoma, gastrointestinal stromal tumor (GIST), Kaposi sarcoma and pediatric cancers such as rhabdomyosarcoma and neuroblastoma.

[0419] The compounds of the invention and methods of treatment comprising the administration or use of an ATR kinase inhibitor or a pharmaceutically acceptable salt thereof are expected to be particularly useful for treating patients suffering from lung cancer, prostate cancer, melanoma, ovarian cancer, breast cancer, endometrial cancer, kidney cancer, gastric cancer, sarcoma, head and neck cancer, tumors of the central nervous system and their metastases, and for treating patients suffering from acute myeloid leukemia.

[0420] The effective amount of the compounds of this invention is usually 0.01mg to 50mg compound / kg patient weight at an average daily dose, preferably 0.1mg to 25mg compound / kg patient weight, with single or multiple administration. Usually, the compounds of this invention can be administered to the patient with this treatment need with a daily dose range of about 1mg to about 3500mg per patient, preferably 10mg to 1000mg. For example, the daily dose of each patient can be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800, 900 or 1000mg. It can be administered once or multiple times every day, every week (or at intervals of several days) or with an intermittent schedule. For example, the compound can be administered once or multiple times every day on a weekly basis (e.g., every Monday), indefinitely or for several weeks, such as 4-10 weeks. Alternatively, the compound may be administered daily for several days (e.g., 2-10 days), then not administered for several days (e.g., 1-30 days), and the cycle may be repeated indefinitely or a given number of times, e.g., 4-10 cycles. For example, the compound of the present invention may be administered daily for 5 days, then interrupted for 9 days, then administered daily for 5 days, then interrupted for 9 days, and so on, repeating the cycle indefinitely or a total of 4-10 times.

[0421] Combination therapy

[0422] The treatment defined herein may be applied as sole therapy or may include conventional surgery or radiotherapy or chemotherapy in addition to the compounds of the invention. Thus, the compounds of the invention may also be used in combination with existing therapeutic agents for the treatment of cancer.

[0423] Suitable agents for combined use include:

[0424] (i) Antiproliferative / antineoplastic drugs used in medical oncology and their combinations, such as alkylating agents (e.g., cisplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, and nitrosoureas); antimetabolites (e.g., antifolates, such as fluorouracils such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytarabine, hydroxyurea, and gemcitabine); antineoplastic antibiotics (e.g., anthracyclines, such as adriamycin, bleomycin, doxorubicin, daunomycin); , epirubicin, idarubicin, mitomycin-C, dactinomycin, and mithramycin); antimitotic agents (e.g., vinca alkaloids, such as vincristine, vinblastine, vindesine, and vinorelbine; and taxanes, such as paclitaxel and docetaxel); and topoisomerase inhibitors (e.g., epipodophyllotoxins, such as etoposide and teniposide, amsacrine, topotecan, and camptothecin);

[0425] (ii) cytostatic agents, such as antiestrogens (e.g., tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), estrogen receptor downregulators (e.g., fulvestrant), antiandrogens (e.g., bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (e.g. goserelin, leuprorelin and buserelin), progestins (e.g. megestrol acetate), aromatase inhibitors (e.g. anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5α-reductase, such as finasteride;

[0426] (iii) anti-invasive agents (e.g., c-Src kinase family inhibitors, such as AZD0530 and dasatinib) and metalloproteinase inhibitors, such as marimastat; and inhibitors of urokinase-type plasminogen activator receptor function);

[0427] (iv) Growth factor function inhibitors: such as growth factor antibodies and growth factor receptor antibodies (such as the anti-erbB2 antibody trastuzumab [Herceptin TM ] and the anti-erbB1 antibody cetuximab [C225]); such inhibitors also include, for example, tyrosine kinase inhibitors, such as inhibitors of the epidermal growth factor family (e.g., EGFR family tyrosine kinase inhibitors, such as gefitinib, erlotinib and CI 1033; and erbB2 tyrosine kinase inhibitors, such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the platelet-derived growth factor family, such as imatinib; inhibitors of serine / threonine kinases (e.g., Ras / Raf signaling inhibitors, such as farnesyl transferase inhibitors, such as sorafenib (BAY43-9006)) and inhibitors of cell signaling through MEK and / or Akt kinases;

[0428] (v) Anti-angiogenic agents, such as those that inhibit the action of vascular endothelial growth factor (e.g., the anti-vascular endothelial growth factor antibody bevacizumab (Avastin TM ); and VEGF receptor tyrosine kinase inhibitors, such as ZD6474, AZD2171, vatalanib and sunitinib, and compounds acting through other mechanisms (e.g. linomide, inhibitors of integrin αvβ3 function and angiostatin)];

[0429] (vi) Vascular disruptors, such as combretastatin;

[0430] (vii) antisense therapies, such as those directed against the targets listed above, such as ISIS 2503;

[0431] (viii) gene therapy approaches, including approaches to replace abnormal genes (e.g., abnormal p53 or abnormal BRCA1 or BRCA2); GDEPT (gene-directed enzyme prodrug therapy) approaches, such as those using cytosine deaminase, thymidine kinase, or bacterial nitroreductase; and approaches to improve a patient's tolerance to chemotherapy or radiation therapy, such as multidrug resistance gene therapy; and

[0432] (ix) Immunotherapeutic methods, including in vitro and in vivo methods for increasing the immunogenicity of a patient's tumor cells, such as transfection with cytokines (e.g., interleukin 2, interleukin 4, or granulocyte-macrophage colony stimulating factor); methods for reducing T-cell anergy; methods using transfected immune cells (e.g., cytokine-transfected dendritic cells); methods using cytokine-transfected tumor cell lines and methods using anti-idiotypic antibodies.

[0433] Example

[0434] The materials or reagents used herein are commercially available or prepared by synthetic methods generally known in the art. The following reaction scheme illustrates a specific synthetic method for the compounds of the present invention.

[0435] The details are as follows:

[0436] Preparation of key intermediates a1-a27:

[0437]

[0438] Add 2,4,6-trichloropyrimidine (13.74mmol, 2.5g), (R)-2-methylmorpholine (13.8mmol, 1.4g) and DIPEA (30mmol, 3.87g) to the reaction bottle. Dissolve in 50mL acetonitrile and react at 90℃ for 2 hours. Stop the reaction, spin dry the solvent, add 50mL water, extract with ethyl acetate, dry with anhydrous Na2SO4, separate by column chromatography, and obtain intermediate a1 (2.3g, yield: 68%), LC-MS: [M+H] + :248.

[0439]

[0440] Under ice bath conditions, add 4-bromo-7-azaindole a2-1 (25.5mmol, 5g) and p-toluenesulfonyl chloride (38.25mmol, 7.27g) to the reaction bottle. Dissolve in 100mL of anhydrous tetrahydrofuran, slowly add 60% NaH (30mmol, 1.2g), and react at room temperature for 6 hours. Stop the reaction, slowly add 50mL of water, spin dry the organic solvent, extract with dichloromethane, dry with anhydrous Na2SO4, and separate by column chromatography to obtain intermediate a2-2 (9.0g, quantitative yield), LC-MS: [M+H] + :350.

[0441] Under nitrogen protection, the intermediate a2-2 (25.5mmol, 9.0g) and bis(boronic acid pinacol) (30.6mmol, 7.77g) were dissolved in 1,4-dioxane, potassium acetate (51mmol, 5g) and Pd(dppf)Cl2 (2.5mmol, 1.83g) were added, and the mixture was reacted at 90°C for 12 hours. The reaction was stopped, filtered, the organic solvent was dried, and column chromatography was performed to obtain the intermediate a2 (10.0g, yield: 98%), LC-MS: [M+H] + :399.

[0442] The following intermediates were synthesized with reference to intermediate a2:

[0443]

[0444]

[0445] Under nitrogen protection, raw materials 3,5-dimethyl-4-bromo-1H-pyrazole a4-2 (2.85mmol, 500mg), 3-bromopyridine a4-1 (3.42mmol, 541mg), potassium phosphate (5.7mmol, 1.24g) and CuI (1.42mmol, 211mg) were added to a microwave reaction bottle and dissolved in 10mL DMF. After stirring for 5 minutes, (1S, 2S)-trans-cyclohexanediamine (2.85mmol, 325mg) was slowly added. The microwave was heated to 150°C for 1 hour to stop the reaction, 40mL of water was added, extracted with ethyl acetate, dried over anhydrous Na2SO4, and separated by flash column chromatography to obtain intermediate a4-3 (400mg, yield: 56%), LC-MS: [M+H] + :253.

[0446] Under nitrogen protection, at -78°C, intermediate a4-3 (1.38 mmol, 350 mg) and isopropoxyboronic acid pinacol ester (4.14 mmol, 0.8 mL) were dissolved in 15 mL of anhydrous THF, butyl lithium (1.38 mL, 2.5 M) was added dropwise, and stirring was continued for 2 hours. 50 mL of saturated aqueous ammonium chloride was added to quench the reaction, and dichloromethane was extracted. Drying over anhydrous sodium sulfate gave a crude intermediate a4, which was directly used in the next step. LC-MS: [M+H] + :300.

[0447] The following intermediates were synthesized with reference to compound a4:

[0448]

[0449]

[0450]

[0451] Under nitrogen protection, raw materials 3,5-dimethyl-4-bromo-1H-pyrazole a4-2 (1.71mmol, 300mg), 3-fluoro-4-bromo-pyridine a16-1 (2.05mmol, 361mg), cesium carbonate (3.42mmol, 1.11g) and CuI (0.86mmol, 164mg) were added to a microwave reaction bottle and dissolved in 10mL DMF. After stirring for 5 minutes, N,N-dimethyl-1,2-cyclohexanediamine (0.86mmol, 123mg) was slowly added. The microwave was heated to 140°C for 50min and then the reaction was stopped. 40mL of water was added, extracted with ethyl acetate, dried over anhydrous Na2SO4, and separated by flash column chromatography to obtain intermediate a16-2 (60mg, yield: 13%), LC-MS: [M+H] + :271.

[0452] Under nitrogen protection, at -78°C, the intermediate a16-2 (0.22mmol, 60mg) and isopropoxyboronic acid pinacol ester (0.66mmol, 0.14mL) were dissolved in 8mL of anhydrous THF, butyl lithium (0.18mL, 2.5M) was added dropwise, and stirring was continued for 2 hours. 20mL of saturated aqueous ammonium chloride solution was added to quench the reaction, and dichloromethane was extracted. Drying over anhydrous sodium sulfate gave 150mg of crude intermediate a16, which was directly used in the next step. LC-MS: [M+H] + :318.

[0453] The following intermediates were synthesized with reference to intermediate a16:

[0454]

[0455]

[0456]

[0457] Under nitrogen protection, raw materials 3,5-dimethyl-4-bromo-1H-pyrazole a4-2 (2mmol, 350mg), 3-chloro-pyridazine a18-1 (2.4mmol, 178mg), potassium phosphate (4mmol, 873mg) and CuI (1mmol, 190mg) were added to a microwave reaction bottle and dissolved in 10mL DMF. After stirring for 5 minutes, N,N-dimethyl-1,2-cyclohexanediamine (1mmol, 142mg) was slowly added. The microwave was heated to 140°C for 1 hour and then the reaction was stopped. 40mL of water was added, extracted with ethyl acetate, dried over anhydrous Na2SO4, and separated by flash column chromatography to obtain intermediate a18-2 (150mg, yield: 30%), LC-MS: [M+H] + :254.

[0458] Under nitrogen protection, add intermediate a18-2 (0.9mmol, 230mg), bis-boronic acid pinacol ester (1.08mmol, 274mg), DIEA (1.8mmol, 232mg) and Pd(Amphos)Cl2 (0.09mmol, 64mg) into a microwave reaction bottle, and dissolve in 10mL 2-Me-THF and MeOH mixed solution (1 / 1, v / v). The microwave was heated to 100℃ for 1 hour and then the reaction was stopped. Filter, add 30mL of water, and extract with ethyl acetate to obtain the crude intermediate a18, which was directly used in the next step. LC-MS: [M+H] + :301.

[0459] The following intermediates were synthesized with reference to intermediate a18:

[0460]

[0461]

[0462] Under nitrogen protection, the raw materials 3,5-dibromopyridine a20-1 (6.33mmol, 1.5g), 1-(trimethylsilyl)propyne a20-2 (6.65mmol, 0.98mL), Pd(PPh3)4 (0.33mmol, 384mg) and CuI (1.89mmol, 362mg) were added to the reaction bottle, and 13mL of tetrahydrofuran and triethylamine mixed solution (v / v, 3 / 1) were dissolved. After stirring for 10 minutes, TBAF (6.64mmol, 1.82mL) was added and the temperature was raised to 60°C for 2 hours to stop the reaction. 60mL of water was added, extracted with ethyl acetate, dried over anhydrous Na2SO4, and separated by flash column chromatography to obtain intermediate a20-3 (900mg, yield: 73%), LC-MS: [M+H] + :197.

[0463] Under nitrogen protection, the raw material 3,5-dimethyl-4-bromo-1H-pyrazole a4-2 (1.14mmol, 200mg), intermediate a20-3 (1.37mmol, 269mg), potassium phosphate (2.28mmol, 498mg) and CuI (0.57mmol, 109mg) were added to the reaction bottle and dissolved in 10mL DMF. After stirring for 5 minutes, N,N-dimethyl-1,2-cyclohexanediamine (0.92mmol, 130mg) was slowly added. The microwave was heated to 100°C for 12 hours and the reaction was stopped. 40mL of water was added, extracted with ethyl acetate, dried over anhydrous Na2SO4, and separated by flash column chromatography to obtain intermediate a20-4 (150mg, yield: 45%), LC-MS: [M+H] +:291.

[0464] Under nitrogen protection, at -78°C, intermediate a20-4 (0.52mmol, 150mg) and isopropoxyboronic acid pinacol ester (1.29mmol, 0.27mL) were dissolved in 12mL of anhydrous THF, butyl lithium (0.63mL, 2.5M) was added dropwise, and stirring was continued for 2 hours. 30mL of saturated aqueous ammonium chloride solution was added to quench the reaction, and dichloromethane was extracted. Drying over anhydrous sodium sulfate gave the crude intermediate a20, which was directly used in the next step. LC-MS: [M+H] + :338.

[0465]

[0466] Under nitrogen protection, the raw materials 5-methyl-3-(trifluoromethyl)-4-bromo-1H-pyrazole a24-1 (2.62mmol, 600mg), 3-fluoro-5-bromo-pyridine a12-1 (3.14mmol, 553mg), potassium phosphate (5.24mmol, 1.14g) and CuI (1.31mmol, 250mg) were added to the reaction bottle, and 15mL DMF was dissolved. After stirring for 5 minutes, N,N-dimethyl-1,2-cyclohexanediamine (2.1mmol, 298mg) was slowly added. The reaction was stopped after heating to 100℃ for 12 hours. Filter, add 50mL of water, extract with ethyl acetate, dry with anhydrous Na2SO4, and separate by flash column chromatography to obtain intermediate a24-2 (900mg, quantitative yield), LC-MS: [M+H] + :325.

[0467] Under nitrogen protection, at -78°C, intermediate a24-2 (1.38 mmol, 450 mg) and isopropoxyboronic acid pinacol ester (3.46 mmol, 0.73 mL) were dissolved in 15 mL of anhydrous THF, butyl lithium (1.67 mL, 2.5 M) was added dropwise, and stirring was continued for 1 hour. 30 mL of saturated aqueous ammonium chloride was added to quench the reaction, and the mixture was extracted with ethyl acetate. Drying over anhydrous sodium sulfate gave the crude intermediate a24, which was directly used in the next step. LC-MS: [M+H] + :372.

[0468]

[0469] Under nitrogen protection, the raw material 5-bromopyridine-3-carboxaldehyde (2.69mmol, 500mg) was dissolved in 8mL of dichloromethane. After stirring for 5 minutes, Et2NSF3 (3.2mmol, 0.429mL) was slowly added. After reacting for 5 hours at room temperature, the reaction was stopped. The system was placed in an ice bath, 30mL of saturated sodium bicarbonate aqueous solution was added, extracted with dichloromethane, dried over anhydrous Na2SO4, and separated by flash column chromatography to obtain intermediate a25-1 (150mg, yield: 27%), LC-MS: [M+H] + :209.

[0470] Under nitrogen protection, the raw material 3,5-dimethyl-4-bromo-1H-pyrazole a4-2 (2.9mmol, 500mg), intermediate a25-1 (2.4mmol, 500mg), potassium phosphate (4.8mmol, 1g) and CuI (0.48mmol, 91mg) were added to the microwave reaction bottle, and 10mL DMF was dissolved. After stirring for 5 minutes, N,N-dimethyl-1,2-cyclohexanediamine (1mmol, 142mg) was slowly added. The microwave was heated to 110°C for 1 hour and the reaction was stopped. 40mL of water was added, extracted with ethyl acetate, dried over anhydrous Na2SO4, and separated by flash column chromatography to obtain intermediate a25-2 (180mg, yield: 25%), LC-MS: [M+H] + :303.

[0471] Under nitrogen protection, at -78°C, intermediate a25-2 (0.6mmol, 180mg) and isopropoxyboronic acid pinacol ester (0.9mmol, 166mg) were dissolved in 6mL of anhydrous THF, butyl lithium (0.48mL, 2.5M) was added dropwise, and stirring was continued for 2 hours. 20mL of saturated aqueous ammonium chloride solution was added to quench the reaction, and dichloromethane was extracted. Drying over anhydrous sodium sulfate gave 210mg of crude intermediate a25, which was directly used in the next step. LC-MS: [M+H] + :350.

[0472] Preparation of key intermediates b1-b8:

[0473]

[0474] Under nitrogen protection, intermediate a1 (4mmol, 1.0g) and intermediate a2 (6mmol, 2.4g) were dissolved in a 10mL mixed solution of 1,4-dioxane and water (v / v: 9 / 1). Sodium carbonate (8mmol, 848mg) and Pd(dppf)Cl2 (0.4mmol, 293mg) were added, and the mixture was heated under reflux for 12 hours. The reaction was stopped, filtered, the organic solvent was dried, water was added, ethyl acetate was extracted, and column chromatography was performed to obtain intermediate b1 (700mg), with a yield of 36%, LC-MS: [M+H] + :484.

[0475] The following compounds were synthesized with reference to intermediate b1:

[0476]

[0477]

[0478]

[0479] Add intermediate a1 (2.02mmol, 500mg) and raw material 2-aminobenzimidazole b2-1 (2.11mmol, 282mg) to a microwave reaction bottle and dissolve in 10mL DMF. Add cesium carbonate (4.03mmol, 1.3g) and react at 100℃ in microwave for 1.5 hours. Stop the reaction, add 40mL of water, extract with ethyl acetate, dry with anhydrous sodium sulfate, separate by flash column chromatography, and obtain intermediate b2 (600mg, yield: 86%), LC-MS: [M+H] + :345.

[0480]

[0481] Add intermediate a1 (40.3mmol, 10g) and raw material 2-nitro-aniline b3-1 (48.4mmol, 6.68g) to the reaction flask and dissolve in 100mL DMA. Add sodium tert-butoxide (81mmol, 7.74g) and react at 90℃ for 12 hours. Stop the reaction, add 300mL of water, filter, and dry over anhydrous sodium sulfate to obtain intermediate b3-2 (16g, crude product). LC-MS: [M+H] + :350.

[0482] Add crude intermediate b3-2 (16 g), reduced iron powder (228.7 mmol, 12.8 g) and ammonium chloride (228.7 mmol, 12.2 g) to the reaction flask, add 200 mL of ethanol and 20 mL of water to dissolve. React at 80 ° C for 1.5 hours. Stop the reaction, filter, evaporate the solvent under reduced pressure, add 200 mL of water, extract with ethyl acetate, and dry over anhydrous sodium sulfate to obtain intermediate b3-3 (12.5 g, crude product), LC-MS: [M+H] + :320.

[0483] Add intermediate b3-3 (6.25mmol, 2.0g) and 20mL pyridine to the reaction bottle to dissolve, slowly add methyl isothiocyanate (7.5mmol, 548mg), and react at 90°C for 0.5 hours. After cooling to room temperature, add EDCI (9.38mmol, 1.8g), continue to heat to 90°C and react overnight to stop the reaction. Add 100mL of water to the system, extract with ethyl acetate, dry with anhydrous sodium sulfate, and separate by flash column chromatography to obtain intermediate b3 (1.2g, yield: 54%), LC-MS: [M+H] + :359.

[0484]

[0485] Under nitrogen protection, the intermediate a1 (0.8mmol, 200mg) and the raw material indol-4-ylboronic acid pinacol ester b5-1 (0.88mmol, 214mg) were dissolved in a 10mL mixed solution of 1,4-dioxane and water (v / v: 9 / 1), potassium carbonate (1.6mmol, 221mg) and Pd(dppf)Cl2 (0.08mmol, 59mg) were added, and heated to 110°C for 2 hours. The reaction was stopped, filtered, 30mL of water was added, extracted with ethyl acetate, and separated by column chromatography to obtain the intermediate b5 (50mg) with a yield of 19%, LC-MS: [M+H] + :329.

[0486] The following compounds were synthesized with reference to intermediate b5:

[0487]

[0488]

[0489] Add intermediate b3-3 (39.4mmol, 12.6g), triethylamine (197mmol, 19.9g) and carbonyldiimidazole (197mmol, 31.9g) to the reaction flask and dissolve in 80mL tetrahydrofuran. Heat to 60℃ and react for 2 hours, then stop the reaction. Add 200mL saturated sodium bicarbonate aqueous solution to the system, extract with ethyl acetate, dry with anhydrous sodium sulfate, separate with column chromatography to obtain intermediate b7-1 (8.0g, yield: 59%), LC-MS: [M+H] + :346.

[0490] Dissolve phosphorus oxybromide (17.35mmol, 4.97g) in 50mL of ethyl acetate, and slowly add intermediate b7-1 (5.78mmol, 2.0g) and triethylamine (17.35mmol, 1.75g). Heat the reaction solution to 90°C for 20 hours to stop the reaction. Place the system in an ice bath and slowly add 100mL of ice water to the system to quench the reaction. Adjust the pH to about 8.0 with saturated sodium bicarbonate aqueous solution, and extract with ethyl acetate. Dry with anhydrous sodium sulfate, separate by column chromatography, and obtain intermediate b7-2 (1.2g, yield: 51%), LC-MS: [M+H] + :409.

[0491] Add intermediate b7-2 (1.47mmol, 600mg), triethylamine (2.94mmol, 298mg) and 2-aminoethanol (2.20mmol, 134mg) to the reaction bottle and dissolve in 10mL tetrahydrofuran. Heat to 60℃ and react for 6 hours, then stop the reaction. Add 50mL water to the system, extract with ethyl acetate, dry with anhydrous sodium sulfate, separate with flash column chromatography to obtain intermediate b7 (420mg, yield: 74%), LC-MS: [M+H] + :389.

[0492] Preparation of key intermediate c1:

[0493]

[0494] Under nitrogen protection, at -5°C, the raw material c1-1 (5mmol, 1.05g) was dissolved in 15mL of fluorobenzene, and diethylzinc (12.5mL, 25mmol, 2N toluene solution) and chloroiodomethane fluorobenzene solution (4.4g / 1.8mL, 25mmol, added three times) were slowly added, and the reaction was carried out at room temperature for 12 hours. The system was placed in an ice bath, 40mL of saturated ammonium chloride aqueous solution was added to quench the reaction, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and separated by column chromatography to obtain intermediate c1-2 (730mg) with a yield of 65%.

[0495] Under nitrogen protection, the intermediate c1-2 (3.23mmol, 730mg) was dissolved in a mixture of 16mL methanol / acetonitrile (1 / 1, v / v), and an aqueous solution of KF (749mg / 3mL) was slowly added. After the system was stirred for 10 minutes, L-tartaric acid (6.46mmol, 968mg) and tetrahydrofuran (350μL) were added, and the reaction was continued at room temperature for 1.5h. The reaction was stopped, filtered, and the filtrate was concentrated to obtain the intermediate c1-3 (600mg, crude product) with a yield of 90%.

[0496] Under nitrogen protection, intermediate c1-3 (7.4mmol, 1.5g), cesium carbonate (22.2mmol, 7.2g) and 2,4,6-trichloropyrimidine (7.4mmol, 1.35g) were dissolved in 36mL of toluene / water (5 / 1, v / v) mixture, and Pd(dppf)Cl2 (0.74mmol, 540mg) was added. The system was heated to 110℃ and reacted overnight, the reaction was stopped, filtered, concentrated, and separated by flash column chromatography to obtain yellow oily intermediate c1 (500mg) with a yield of 27%, LC-MS: [M+H] + :246.

[0497] Embodiment 1:

[0498]

[0499] Under nitrogen protection, intermediate b6 (0.37mmol, 130mg) and intermediate a9 (0.56mmol, 185mg) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (0.75mmol, 104mg) and Pd(dppf)Cl2 (0.04mmol, 28mg) were added. The reaction was heated at 90°C for 12 hours. The reaction was stopped, filtered, 40mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, separated by flash column chromatography, and separated by preparative chromatography to obtain compound A1 (24mg, yield: 13%). LC-MS: [M+H] + :514.

[0500] The following compounds were synthesized by referring to the route of Example 1:

[0501]

[0502]

[0503]

[0504]

[0505]

[0506] Embodiment 2:

[0507]

[0508] Under nitrogen protection, intermediate b3 (0.23mmol, 84mg) and intermediate a12 (0.35mmol, crude product) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (0.46mmol, 64mg) and Pd(dppf)Cl2 (0.024mmol, 17mg) were added. The reaction was heated at 90°C for 12 hours. The reaction was stopped, filtered, 40mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, separated by flash column chromatography, and separated by preparative chromatography to obtain compound B1 (24mg, yield: 21%). LC-MS: [M+H] + :514.

[0509] The following compounds were synthesized by referring to the route of Example 2:

[0510]

[0511]

[0512]

[0513] Embodiment 3:

[0514]

[0515] Under nitrogen protection, intermediate b5 (1.36mmol, 450mg) and intermediate a12 (2.04mmol, crude product) were dissolved in 20mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (2.72mmol, 376mg) and Pd(dppf)Cl2 (0.14mmol, 100mg) were added. The reaction was heated at 90°C for 12 hours. The reaction was stopped, filtered, 50mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, separated by flash column chromatography, and separated by preparative chromatography to obtain compound A17 (183mg, yield: 28%). LC-MS: [M+H] + :484.

[0516] 1H NMR (400MHz, DMSO-d6) δ11.24(s,1H),8.77–8.75(m,1H),8.70(dd,J=2.6,0.5Hz,1H),8.16(dd,J=7.5,1.0Hz,1H),8.1 2(ddd,J=9.8,2.6,2.1Hz,1H),7.54(t,J=0.9Hz,1H),7.46–7.43(m,1H),7.36(dq,J=2.1,1.0Hz,1H),7.20(t,J=7.8Hz ,1H),6.68(s,1H),4.59(d,J=6.4Hz,1H),4.25(d,J=12.8Hz,1H),4.03(dd,J=11.4,3.6Hz,1H),3.82(d,J=11.3Hz,1H) ,3.71(dd,J=11.3,3.1Hz,1H),3.61–3.51(m,1H),3.31–3.25(m,1H),2.63(s,3H),2.49(s,3H),1.31(d,J=6.7Hz,3H).

[0517] Embodiment 4:

[0518]

[0519] Under nitrogen protection, intermediate b1 (0.4mmol, 194mg) and intermediate a22 (0.6mmol, crude product) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), potassium carbonate (0.8mmol, 110mg) and Pd(dppf)Cl2 (0.04mmol, 30mg) were added, and the mixture was heated at 100°C for 1 hour. The reaction was stopped, filtered, the organic solvent was evaporated under reduced pressure, 40mL of water was added, and the mixture was extracted with ethyl acetate to obtain a crude compound A18-1 (300mg), LC-MS: [M+H] + :656.

[0520] Compound A18-1 (300 mg) was dissolved in a mixed solution of 10 mL THF / MeOH (v / v, 1:1), cesium carbonate (0.92 mmol, 299 mg) was added, and the mixture was reacted at 70°C for 1 hour. The reaction was stopped, filtered, 30 mL of water was added, and the mixture was extracted with ethyl acetate and separated by preparative chromatography to obtain the target compound A18 (71 mg, total yield of two steps: 36%). LC-MS: [M+H] + :501.

[0521] The following compounds were synthesized by referring to the route of Example 4:

[0522]

[0523]

[0524] Embodiment 5:

[0525]

[0526] Under nitrogen protection, intermediate b3 (0.28mmol, 100mg) and intermediate a23 (0.34mmol, 212mg) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (0.84mmol, 116mg) and Pd(dppf)Cl2 (0.028mmol, 20mg) were added. The reaction was heated at 100°C for 2 hours. The reaction was stopped, filtered, 30mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, separated by flash column chromatography, and separated by preparative chromatography to obtain compound B9-1 (70mg, yield: 43%). LC-MS: [M+H] + :602.

[0527] Compound B9-1 (0.25mmol, 150mg) was dissolved in 8mL methanol and 3mL concentrated hydrochloric acid was added. The reaction was heated at 65°C for 2 hours. The reaction was stopped, the reaction solution was placed in an ice bath, and saturated NaHCO3 aqueous solution was slowly added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and separated by flash column chromatography to obtain compound B9 (108mg, yield: 85%). LC-MS: [M+H] + :512.

[0528] The following compounds were synthesized by referring to the route of Example 5:

[0529]

[0530]

[0531] Example 6: B10

[0532]

[0533] Compound B4 (0.057 mmol, 30 mg) was dissolved in a mixed solution of 6 mL of water and acetonitrile (v / v, 5 / 1), and manganese dioxide (0.115 mmol, 10 mg) was added. The mixture was heated at 90°C for 10 hours. The reaction was stopped, filtered, and separated by flash column chromatography to obtain compound B10 (20 mg, yield: 65%). LC-MS: [M+H] + :539.

[0534] 1H NMR (400MHz, DMSO-d6) δ9.11(d,J=1.8Hz,1H),9.00(d,J=2.4Hz,1H),8.63(q,J=4.7Hz,1H),8.42(t,J=2.1Hz,1H),8.3 3(s,1H,(C=O)NH),8.23(d,J=7.1Hz,1H),7.79(s,1H,(C=O)NH),7.27(d,J=7.9Hz,1H),7.10(t,J=8.0Hz,1H),7.01(t,J =7.3Hz,1H),6.72(s,1H),4.52(s,1H),4.13(d,J=11.2Hz,1H),4.05(d,J=7.3Hz,1H),3.83(d,J=12.1Hz,1H),3.76–3.6 8(m,1H),3.64–3.52(m,1H),3.43–3.35(m,1H),3.10(d,J=4.8Hz,3H),2.56(s,3H),2.46(s,3H),1.34(d,J=6.8Hz,3H).

[0535] Example 7: B11

[0536]

[0537] Under nitrogen protection, intermediate b7 (0.38mmol, 150mg) and intermediate a12 (0.77mmol, 247mg) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (1.16mmol, 160mg) and Pd(dppf)Cl2 (0.077mmol, 56mg) were added. The reaction was heated at 100°C for 2 hours. The reaction was stopped, filtered, 30mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, separated by flash column chromatography, and separated by preparative chromatography to obtain compound B11 (94mg, yield: 46%). LC-MS: [M+H] + :544.

[0538] 1H NMR (400MHz, DMSO-d6) δ8.83(t,J=5.5Hz,1H),8.75(dd,J=1.7,1.1Hz,1H),8.72(dd,J=2.6,0.4Hz,1H),8.28–8.24(m ,1H),8.09(ddd,J=9.7,2.6,2.1Hz,1H),7.27–7.24(m,1H),7.10(td,J=7.6,1.2Hz,1H),7.03–6.97(m,1H),6.71(s,1 H),4.92(t,J=5.0Hz,1H),4.51(s,1H),4.14(d,J=13.6Hz,1H),4.03(dd,J=11.3,3.6Hz,1H),3.81(d,J=11.5Hz,1H), 3.74–3.63(m,3H),3.63–3.52(m,3H),3.37(dd,J=13.0,3.8Hz,1H),2.58(s,3H),2.45(s,3H),1.32(d,J=6.7Hz,3H).

[0539] Example 8: A22

[0540]

[0541] Under nitrogen protection, intermediate b8 (0.57mmol, 220mg) and intermediate a12 (0.85mmol, 270mg) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (1.71mmol, 256mg) and Pd(dppf)Cl2 (0.114mmol, 84mg) were added. The reaction was heated at 100°C for 2 hours. The reaction was stopped, filtered, 30mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, separated by flash column chromatography, and separated by preparative chromatography to obtain compound A22-1 (260mg, yield: 85%). LC-MS: [M+H] + :542.

[0542] Under nitrogen protection, compound A22-1 (0.29 mmol, 160 mg) was dissolved in 5 mL of anhydrous tetrahydrofuran in an ice bath. Lithium aluminum tetrahydride (0.3 mL, 2.5 M) was slowly added, and the reaction was continued for 3 hours in an ice bath, and the reaction was stopped. 10 mL of methanol and 50 mL of water were added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and separated by preparative chromatography to obtain compound A22 (57 mg, yield: 39%). LC-MS: [M+H] + :514.

[0543] 1H NMR (400MHz, DMSO-d6) δ11.18(s,1H),8.76(t,J=1.7Hz,1H),8.71(d,J=2.6Hz,1H),8.12(m,2H),7.50(d ,J=1.3Hz,1H),7.40(t,J=2.8Hz,1H),7.31(q,J=1.8,0.9Hz,1H),6.68(s,1H),5.16(t,J=5.7Hz,1H),4.6 5(d,J=5.8Hz,2H),4.58(s,1H),4.26(d,J=13.1Hz,1H),4.08–4.01(m,1H),3.83(d,J=11.4Hz,1H),3.71( dd,J=11.4,3.1Hz,1H),3.60–3.53(m,1H),3.28(m,1H),2.63(s,3H),2.49(s,3H),1.31(d,J=6.7Hz,3H).

[0544] Example 9: B12

[0545]

[0546] Under nitrogen protection, intermediate b3 (0.58mmol, 200mg) and intermediate a12 (1.45mmol, 460mg) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (1.16mmol, 160mg) and Pd(dppf)Cl2 (0.058mmol, 43mg) were added. The mixture was heated at 100°C for 2 hours. The reaction was stopped, filtered, 30mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, separated by flash column chromatography, and separated by preparative chromatography to obtain compound B12 (71mg, yield: 25%). LC-MS: [M+H] + :500.

[0547] 1H NMR (400MHz, DMSO-d6) δ8.76–8.74(m,1H),8.72(d,J=2.6Hz,1H),8.20(d,J=7.8Hz,1H),8.14–8.09(m, 1H),7.74(br,2H),7.19(s,1H),7.09(td,J=7.5,1.1Hz,1H),6.99(td,J=7.8,1.2Hz,1H),6.71(s,1H),4 .49(s,1H),4.12(d,J=12.2Hz,1H),4.07–4.00(m,1H),3.82(d,J=11.3Hz,1H),3.71(dd,J=12.1,3.2Hz ,1H),3.61–3.52(m,1H),3.38(dd,J=12.8,4.4Hz,1H),2.55(s,3H),2.43(s,3H),1.33(d,J=6.8Hz,3H).

[0548] Example 10: A23

[0549]

[0550] Under nitrogen protection, intermediate b5 (0.46mmol, 150mg) and intermediate a26 (0.68mmol, 277mg) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (1.37mmol, 189mg) and Pd(dppf)Cl2 (0.09mmol, 67mg) were added. The reaction was heated at 100°C for 2 hours. The reaction was stopped, filtered, 30mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and separated by flash column chromatography to obtain compound A23-1 (160mg, yield: 62%). LC-MS: [M+H] + :572.

[0551] Under nitrogen protection, compound A23-1 (0.10 mmol, 60 mg) was dissolved in a mixed solution of 5 mL methanol and ethyl acetate (v / v, 3 / 2), and Pd / C (10 mg) was added. The reaction was heated at 50°C for 1 hour, the reaction was stopped, filtered, and separated by preparative chromatography to obtain compound A23 (30 mg, yield: 63%). LC-MS: [M+H] + :482.

[0552] 1H NMR (400MHz, DMSO-d6) δ11.25(s,1H),10.50(br,1H),8.27(d,J=2.1Hz,1H),8.21(d,J=2.5Hz,1H),8.16(dd ,J=7.6,1.0Hz,1H),7.53(d,J=8.0Hz,1H),7.44(t,J=2.7Hz,1H),7.37(t,J=2.3Hz,2H),7.20(t,J=7.8Hz,1H ),6.69(s,1H),4.59(s,1H),4.25(d,J=13.3Hz,1H),4.03(dd,J=11.0,3.6Hz,1H),3.82(d,J=11.4Hz,1H),3. 71(dd,J=11.3,3.1Hz,1H),3.60–3.53(m,1H),3.27(m,1H),2.58(s,3H),2.48(s,3H),1.30(d,J=6.7Hz,3H).

[0553] Example 11: C1

[0554]

[0555] At -50°C, cyanuric chloride (110 mmol, 1.97 g) and DIPEA (210 mmol, 2.76 g) were dissolved in 70 mL of dichloromethane, and (R)-2-methylmorpholine (110 mmol, 1.08 g) was slowly added dropwise. After stirring at -50°C for 1 hour, 50 mL of 1N HCl aqueous solution was added to quench the reaction, and dichloromethane was extracted. Drying over anhydrous sodium sulfate, filtering, and drying the solvent to obtain C1-1 (2.5 g, yield: 92%). LC-MS: [M+H] + :249.

[0556] Under nitrogen protection, C1-1 (0.4mmol, 100mg), intermediate b5-1 (0.8mmol, 195mg), potassium carbonate (1.2mmol, 166mg) and Pd(PPh3)4 (0.04mmol, 46mg) were dissolved in 5mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and heated at 80°C for 12 hours. The reaction was stopped, filtered, the organic solvent was evaporated under reduced pressure, water was added, ethyl acetate was extracted, and column chromatography was performed to obtain compound C1-2 (100mg, yield: 76%), LC-MS: [M+H] + :330.

[0557] Under nitrogen protection, C1-2 (0.68mmol, 224mg), intermediate a12 (0.82mmol, 259mg), potassium carbonate (2.04mmol, 281mg) and Pd(dppf)Cl2 (0.068mmol, 50mg) were dissolved in 5mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and reacted at 100°C for 2 hours. The reaction was stopped, filtered, 20mL of water was added, extracted with ethyl acetate, and separated by flash column chromatography to obtain compound C1 (200mg, yield: 61%), LC-MS: [M+H] + :485.

[0558] 1 H NMR (400MHz, DMSO-d6) δ11.41(s,1H),8.77(t,J=1.6Hz,1H),8.74(d,J=2.6Hz,1H),8.29(dd,J=7. 6,1.0Hz,1H),8.16(m,1H),7.65(dd,J=8.0,1.0Hz,1H),7.53(t,J=2.8Hz,1H),7.36(m,1H),7.26( t,J=7.8Hz,1H),4.87(d,J=45.2Hz,1H),4.52(d,J=38.4Hz,1H),4.05(s,1H),3.84(d,J=11.5Hz,1 H),3.70(d,J=11.0Hz,1H),3.59–3.50(m,1H),3.40(s,1H),2.83(s,3H),2.66(s,3H),1.36(s,3H).

[0559] Example 12: C2

[0560]

[0561] Under nitrogen protection, intermediate c1 (1.37mmol, 335mg), intermediate a12 (1.51mmol, 684mg), sodium carbonate (4.11mmol, 435mg) and Pd(dppf)Cl2 (0.14mmol, 100mg) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and heated at 100°C for 2 hours. The reaction was stopped, filtered, the organic solvent was evaporated under reduced pressure, water was added, ethyl acetate was extracted, and column chromatography was performed to obtain compound C2-1 (500mg, yield: 91%), LC-MS: [M+H] + :400.

[0562] Under nitrogen protection, intermediate C2-1 (0.3mmol, 120mg), intermediate b6-1 (0.36mmol, 93mg), potassium carbonate (0.9mmol, 120mg) and Pd(dppf)Cl2 (0.03mmol, 21mg) were dissolved in 5mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and reacted at 100°C for 2 hours. The reaction was stopped, filtered, 20mL of water was added, extracted with ethyl acetate, and separated by flash column chromatography to obtain compound C2 (30mg, yield: 21%), LC-MS: [M+H] + :499.

[0563] 1 H NMR (400MHz, DMSO-d6) δ11.40(s,1H),8.78(t,J=1.6Hz,1H),8.73(d,J=2.5Hz,1H),8.15(dt,J=9.7, 2.4Hz,1H),8.00(dd,J=11.5,2.5Hz,1H),7.51(t,J=2.8Hz,1H),7.41–7.35(m,3H),4.01(dd,J=11.4 ,4.6Hz,1H),3.92(dd,J=11.4,1.6Hz,1H),3.67–3.61(m,1H),3.50–3.44(m,1H),2.77(dd,J=13.9,5 .2Hz,1H),2.66(s,3H),2.53(s,3H),2.15–2.08(m,1H),2.06–2.01(m,1H),1.61(m,1H),1.27(m,1H).

[0564] Example 13: C3

[0565]

[0566] Under nitrogen protection, compound C2-1 (0.3mmol, 120mg), intermediate b5-1 (0.36mmol, 90mg), potassium carbonate (0.9mmol, 120mg) and Pd(dppf)Cl2 (0.03mmol, 21mg) were dissolved in 5mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and reacted at 100°C for 2 hours. The reaction was stopped, filtered, 20mL of water was added, extracted with ethyl acetate, and separated by flash column chromatography to obtain compound C3 (30mg, yield: 22%), LC-MS: [M+H] + :481.

[0567] 1H NMR (400MHz, DMSO-d6) δ11.32(s,1H),8.78(t,J=1.6Hz,1H),8.73(d,J=2.6Hz,1H),8.24(dd,J=7.6,1.0Hz,1H),8.15 (dt,J=9.7,2.4Hz,1H),7.58(dd,J=8.0,1.0Hz,1H),7.49(t,J=2.8Hz,1H),7.40–7.37(m,1H),7.32(s,1H),7.24(t,J= 7.8Hz,1H),4.01(dd,J=11.3,4.6Hz,1H),3.92(dd,J=11.3,1.5Hz,1H),3.65(dd,J=11.3,5.5Hz,1H),3.50–3.44(m,1H ),2.80–2.74(m,1H),2.66(s,3H),2.53(s,3H),2.16–2.09(m,1H),2.06–2.00(m,1H),1.61(m,1H),1.27–1.24(m,1H).

[0568] Example 14: A24

[0569]

[0570] Under nitrogen protection, intermediate b5 (0.43mmol, 140mg) and intermediate a10 (0.86mmol, crude product) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (0.86mmol, 119mg) and Pd(dppf)Cl2 (0.04mmol, 30mg) were added. The reaction was heated at 90°C for 12 hours. The reaction was stopped, filtered, 30mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and separated by flash column chromatography to obtain compound A24-1 (150mg, yield: 71%). LC-MS: [M+H] + :491.

[0571] The intermediate A24-1 in the previous step was dissolved in a mixed solution of 10 mL of water and acetonitrile (v / v=4 / 1), and manganese dioxide (0.62 mmol, 54 mg) was added, and the temperature was raised to 90°C for reaction for 10 hours, and the reaction was stopped, cooled to room temperature, extracted with ethyl acetate, and separated by preparative chromatography to obtain the target compound A24 (10 mg, yield: 7%). LC-MS: [M+H] + :509.

[0572] 1H NMR (400MHz, DMSO-d6) δ11.24(s,1H),9.10(d,J=2.0Hz,1H),8.98(d,J=2.4Hz,1H),8.42(t,J=2.2Hz,1H),8.33 (s,1H),8.17(dd,J=7.6,1.0Hz,1H),7.79(s,1H),7.55–7.52(m,1H),7.45(t,J=2.7Hz,1H),7.38–7.35(m,1H), 7.20(t,J=7.7Hz,1H),6.70(s,1H),4.60(s,2H),4.26(d,J=13.4Hz,1H),4.06–4.02(m,1H),3.82(d,J=11.4Hz, 1H),3.71(dd,J=11.3,3.1Hz,1H),3.60–3.54(m,1H),3.27(d,J=7.0Hz,1H),2.63(s,3H),1.31(d,J=6.7Hz,3H).

[0573] Example 15: B13

[0574]

[0575] Under nitrogen protection, intermediate b7 (0.38mmol, 150mg) and intermediate a23 (0.77mmol, 312mg) were dissolved in 10mL of a mixture of 1,4-dioxane and water (v / v: 9 / 1), and potassium carbonate (1.16mmol, 160mg) and Pd(dppf)Cl2 (0.077mmol, 56mg) were added. The reaction was heated at 110°C for 2 hours. The reaction was stopped, filtered, 30mL of water was added to the system, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and separated by flash column chromatography to obtain compound B13-1 (200mg, yield: 84%). LC-MS: [M+H] + :632.

[0576] Dissolve the intermediate B13-1 (0.32mmol, 200mg) in 10mL methanol and add 3.5mL concentrated hydrochloric acid. Heat the reaction at 65°C for 2 hours. Stop the reaction, place the reaction solution in an ice bath, and slowly add saturated NaHCO3 aqueous solution to the system to adjust the pH to about 8. Extract with ethyl acetate, dry with anhydrous sodium sulfate, and separate by preparative chromatography to obtain the target compound B13 (95mg, yield: 55%). LC-MS: [M+H] + :542.

[0577] 1H NMR (400MHz, DMSO-d6) δ11.97(s,1H),8.83(s,1H),8.28–8.23(m,1H),7.74(d,J=2.9Hz,1H),7.61(dd,J =9.7,2.9Hz,1H),7.25(dd,J=7.8,1.3Hz,1H),7.10(td,J=7.6,1.2Hz,1H),7.00(td,J=7.7,1.3Hz,1H), 6.65(s,1H),6.48(d,J=9.7Hz,1H),4.91(s,1H),4.50(s,1H),4.12(d,J=13.2Hz,1H),4.02(dd,J=11.4, 3.7Hz,1H),3.81(d,J=11.6Hz,1H),3.74–3.51(m,6H),2.44(s,3H),2.41(s,3H),1.31(d,J=6.7Hz,3H).

[0578] Example 16: ATR kinase activity assay:

[0579] ATR kinase was used to phosphorylate a protein derived from p53 biotinylated (Eurofins, Catalog No. 14-952). The experiment used time-resolved fluorescence to determine the amount of phosphorylated protein. Anti-p53-phospho-(serine 15)-K-specific antibody (Cisbio, Catalog No. 61GSTDLA) and d2-labeled anti-GST antibody (Cisbio, Catalog No. 61P08KAE) were used to detect the amount of phosphorylated protein. Before the experiment, the following working solutions were prepared as needed: 1× reaction buffer (20 mM HEPES PH8.0, 1% glycerol, 0.01% Brij-35), dilution buffer (20 mM HEPES PH8.0, 1% glycerol, 0.01% Brij-35, 5 mM DTT and 1% BSA), stop solution (20 mM HEPES PH8.0, 1% glycerol, 0.01% Brij-35, 250 mM EDTA), detection buffer (50 mM HEPES PH7.0, 150 mM NaCl, 267 mM KF, 0.1% sodium cholate, 0.01% Tween-20, 0.0125% sodium azide). All the above reagents were purchased from Sigma or Invitrogen unless otherwise specified.

[0580] Proceed as follows:

[0581] Prepare 4× gradient dilution compound solution with 1× reaction buffer to obtain 9 different concentrations of compound, and add 2.5μL of 4× gradient dilution compound solution to 384-well assay plate (784075, Greiner). Prepare 4× p53 substrate working solution (40nM) with 1× reaction buffer, and add 2.5μL of 4× p53 substrate working solution to 384-well assay plate. Prepare 4× ATR / ATRIP working solution (12.8ng / μL) with dilution buffer, and add 2.5μL of 4× ATR / ATRIP working solution to 384-well assay plate. Prepare 4× ATP working solution (2mM) with deionized water, add 2.5μL of 4× ATP working solution to 384-well assay plate, and incubate at room temperature for 30 minutes in the dark. Add 5μL of stop solution to 384 assay plate. Finally, add 5 μL of detection mixture (0.084 ng / μL of Anti-phospho-p53 (ser15)-K and 5 ng / μL of Anti-GST-d2) to the 384-well assay plate. Incubate overnight at room temperature and detect the fluorescence signal using ENVISION (Perkinelmer) instrument (excitation wavelength is 320 nm, emission wavelength is 665 nm and 615 nm). The inhibition rate in each well is calculated by the fluorescence intensity value of each well: ER (Emission Ratio, emission ratio) = (fluorescence intensity at 665 nm / fluorescence intensity at 615 nm); Inhibition rate = (ER positive-ER test compound) / (ER positive-ER negative) × 100%, and the IC of the compound is calculated using parameter fitting standard software (GraphPad Prism 6.0) 50 Numeric value.

[0582] Example kinase data results:

[0583] serial number ATR / IC50 / nM serial number ATR / IC50 / nM A1 11 A24 1 A2 8 A25 7 A3 29 B1 11 A4 10 B2 22 A5 30 B3 49 A6 14 B4 17 A7 6 B5 16 A8 9 B6 13 A9 16 B7 62 A10 20 B8 69 A11 10 B9 3 A12 36 B10 5 A13 88 B11 15 A14 9 B12 3 A15 2 B13 5 A16 1 C1 18 A17 5 C2 13 A18 1 C3 16 A19 2 A20 11 A21 6 A22 5 A23 3

[0584] Example 17: In vitro cell proliferation inhibition experiment:

[0585] This experiment studied the inhibitory effect of the compounds on cell proliferation by detecting the effects of the compounds on in vitro cell activity in tumor cell lines TOV21G (ovarian cancer) and MV4-11 (leukemia).

[0586] TOV21G cells and MV4-11 cells were purchased from the American Type Culture Collection (ATCC).

[0587] TOV21G cells were cultured in MCDB105 / M199 medium (containing 15% FBS) and used for the test when the cell confluence reached more than 85%. About 1000 cells were inoculated in each well of a 96-well culture plate and cultured for 24 hours. Different concentrations of the test compound (0-10μM) were added to treat the cells, and 3 parallel wells were set up for each group. Blank wells (containing only culture medium) and control wells (inoculated cells without drug treatment) were set up. After 120 hours of culture, 40μL Cell Titer-Glo solution (Promega, #G7573) was added to each well, incubated in the dark for 20 minutes, and 100μL was transferred from each well to a 96-well white plate (Corning, #3917). The luminescence value was read using a BiotekSynergy H1 multi-function microplate reader.

[0588] MV-4-11 cells were cultured in IMDM medium (containing 20% ​​FBS), and about 10,000 cells were inoculated in each well of a 96-well culture plate. Different concentrations of the test compound (0-10 μM) were added to treat the cells, and 3 parallel wells were set up for each group. Blank wells (containing only culture medium) and control wells (inoculated cells without drug treatment) were set up. After 120 hours of culture, 40 μL of CellTiter-Glo solution was added to each well, and the cells were incubated for 20 minutes in a dark environment. 100 μL of each well was transferred to a 96-well white plate, and the luminescence value was read using a Biotek SynergyH1 multifunctional microplate reader.

[0589] Inhibition rate (%) = 100% × (control well - test well) / (control well - blank well)

[0590] The results of the proliferation assay demonstrated that the tested compounds were effective in the human tumor cells studied, as measured by IC 50 Value reflects (IC 50 is the inhibitory concentration at 50% of the maximum efficacy).

[0591] CellTiter-Glo luminescence cell activity test results

[0592]

[0593] NT = Not Tested

[0594] Example 18: In vitro liver microsome stability test of compounds:

[0595] Based on the in vitro activity results, representative compounds were selected for liver microsome stability experiments, and the results are as follows.

[0596]

[0597] Example 19: In vivo pharmacokinetic experiments of compounds:

[0598] Based on the in vitro activity results, representative compounds were selected for in vivo pharmacokinetic studies, and the results are as follows.

[0599] In vivo oral administration-mice pharmacokinetic results:

[0600]

[0601] Example 20: Study on the selectivity of compounds for ATR kinase:

[0602] The compounds of the present invention were tested in the same family (ATM, DNA-PK and mTOR) inhibition experiment:

[0603] According to the experimental method reported in the literature, the test compound was diluted 3 times to 0.51nM (a total of 10 concentrations) starting from 10μM, and its effects on kinase ATM were measured respectively. 1 ,DNA-PK 2 and mTOR 3 The inhibitory activity of

[0604]

[0605] The above results indicate that the compounds of the present invention are highly selective for ATR and have low inhibitory activity for other kinases in the family.

[0606] References:

[0607] [1] Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase, J. Med. Chem. 2016, 56, 6281-6292;

[0608] [2]The Discovery of7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-puri n-8-one(AZD7648), a Potent and Selective DNA-Dependent Protein Kinase(DNA-PK)Inhibitor,J.Med.Chem.2020,63,3461-3471;

[0609] [3]Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors. Bioorg. Med. Chem. Lett. 2011; 21:6793-6799.

[0610] The above contents are further detailed descriptions of the present invention in combination with specific preferred embodiments, and it cannot be determined that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the protection scope of the present invention.

Claims

1. A compound of general formula (I), or a pharmaceutically acceptable salt thereof: in, X is CR X or N; Y is CR Y or N; R1 is H, D, halogen or C 1-6 Alkyl; wherein the C 1-6 Alkyl is optionally substituted with one or more D or halogen until fully substituted; R2, R3, R4 are independently selected from H, D or halogen; Where R X H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; When Y is CR Y When R Y , R1 together with the atoms to which they are attached form C 3-5 Cycloalkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; Ring A is phenyl or a 5-6 membered heteroaryl group; R a independently selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; m = 0, 1, 2, 3, 4 or 5; Ring B is selected from the following groups: B2 is CR b2 or N; B3 is CR b3 or N; R b2 , R b3 , R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; n=0, 1, 2, 3, 4 or 5; R5 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R6 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R7 and R8 are independently selected from H, D or C optionally substituted with r R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; r = 0, 1, 2, 3, 4 or 5; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from the following groups: Among them, A1 is CR a1 or N; A2 is CR a2 or N; A3 is CR a3 or N; A4 is CR a4 or N; A5 is CR a5 or N; R a1 , R a2 , R a3 , R a4 and R a5 Having the same R as in claim 1 a Same definition.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from the following groups: Among them, A3 is CR a3 or N; A4 is CR a4 or N; A5 is CR a5 or N; R a1 , R a2 , R a3 , R a4 and R a5 Having the same R as in claim 1 a Same definition.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from the following groups: Among them, R a1 , R a2 , R a3 and R a5 Having the same R as in claim 1 a Same definition.

5. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from the following groups:

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of the general formula (V-1): in, A1 is CR a1 or N; A2 is CR a2 or N; A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 or N; R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R5 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R6 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R7 and R8 are independently H, D, or C optionally substituted with r R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R* is H, D, -OH or halogen; r = 0, 1, 2, 3, 4 or 5; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of the general formula (VI-1): in, R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R5 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R6 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R7 and R8 are independently H, D or C optionally substituted with r R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R* is H, D, -OH or halogen; r = 0, 1, 2, 3, 4 or 5; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

8. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein A1 is CR a1 ; A2 is CR a2 or N; A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 ; R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -C(O)NRR', -CN, -NRR' or -OH optionally substituted with R*; R b is H, D or halogen; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R7 and R8 are independently H, D, C optionally substituted with r R* 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, D, -OH or halogen; r = 0, 1, 2, 3, 4 or 5; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

9. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R a1 , R a2 , R a3 and R a5 independently selected from H, D, halogen, -C(O)NRR', -CN, -NRR' or -OH optionally substituted with R*; R b is H, D or halogen; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R7 and R8 are independently H, D, C optionally substituted with r R* 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, -OH or halogen; r = 0, 1, 2, 3, 4 or 5; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

10. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R a1 , R a4 and R a5 independently H or D; R a2 and R a3 are independently H, D, halogen, -C(O)NRR', -CN, -NRR' or -OH; R1 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R7 and R8 are independently H, D, C optionally substituted with r R* 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, D, -OH or halogen; r = 0, 1, 2, 3, 4 or 5; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

11. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R a1 and R a5 independently H or D; R a2 and R a3 are independently H, D, halogen, -C(O)NRR', -CN, -NRR' or -OH; R1 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R7 and R8 are independently H, D, C optionally substituted with r R* 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

12. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein A1 is CR a1 ; A2 is CR a2 ; A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 ; R a1 , R a2 , R a3 , R a4 and R a5 are independently H, D, halogen, C(O)NH2 or -OH; R b is H, D or halogen; n = 0, 1, 2, 3 or 4; R1 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R7 and R8 are independently H, D, C optionally substituted with r R* 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, D, -OH or halogen; r = 0, 1, 2, 3, 4 or 5; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

13. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R a1 , R a2 , R a3 and R a5 are independently H, D, halogen, C(O)NH2 or -OH; R b is H, D or halogen; n = 0, 1, 2, 3 or 4; R1 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R7 and R8 are independently H, D, C optionally substituted with r R* 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, D, -OH or halogen; r = 0, 1, 2, 3, 4 or 5; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R a1 , R a4 and R a5 is H or D; R a2 and R a3 is H, D, halogen, C(O)NH2 or -OH; R1 is C 1-6 Alkyl or C 1-6 Haloalkyl; R5 is C 1-6 Alkyl or C 1-6 Haloalkyl; R6 is C 1-6 Alkyl or C 1-6 Haloalkyl; R7 and R8 are independently H, C 1-6 Alkyl or C 1-6 Haloalkyl; R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein R1 is methyl.

16. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein R5 is methyl or -CF3.

17. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein R6 is methyl or -CF3.

18. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein R a1 and R a5 is H or D; R a2 and R a3 is H, D, halogen, C(O)NH2 or -OH; R1 is C 1-6 Alkyl or C 1-6 Haloalkyl; R5 is C 1-6 Alkyl or C 1-6 Haloalkyl; R6 is C 1-6 Alkyl or C 1-6 Haloalkyl; R7 and R8 are independently H, C 1-6 Alkyl or C 1-6 Haloalkyl; R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R1 is methyl.

20. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R5 is methyl or -CF3.

21. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R6 is methyl or -CF3.

22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula (V-2): in, A1 is CR a1 or N; A2 is CR a2 ; A3 is CR a3 or N; A4 is N; A5 is CR a5 or N; B2 is CR b2 ; B3 is CR b3 ; R a1 , R a2 , R a3 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b2 , R b3 , R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen or C 1-6 Alkyl; wherein the group is optionally substituted by one or more D or halogen until fully substituted; R5 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R6 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

23. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein A1 is CR a1 or N; A2 is CR a2 ; A3 is CR a3 or N; A4 is N; A5 is CR a5 or N; B2 is CR b2 ; B3 is CR b3 ; R a1 , R a2 , R a3 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b2 , R b3 , R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R5 is halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R6 is halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

24. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein A1 is CR a1 or N; A2 is CR a2 ; A3 is CR a3 or N; A4 is N; A5 is CR a5 or N; B2 is CR b2 ; B3 is CR b3 ; R a1 is H, D, halogen or -CN; R a2 is selected from H, D, halogen, -NRR', -OR, -C(O)R or -C(O)NRR' optionally substituted with R*, wherein said groups are optionally substituted with one or more D up to full deuteration; R a3 is selected from H, D, halogen, -CN, -NH2, -OH, -C(O)R or -C(O)NRR', wherein the group is optionally substituted by one or more D or halogen until fully substituted; R a5 is selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b2 is selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b3 is selected from H, D or halogen optionally substituted with R*; R b is H, D or halogen; n = 0, 1, 2, 3 or 4; R1 is halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R5 is halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R6 is halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

25. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein A1 is CR a1 or N; A2 is CR a2 ; A3 is CR a3 or N; A4 is N; A5 is CR a5 or N; B2 is CR b2 ; B3 is CR b3 ; R a1 is H or D; R a2 is selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R or -C(O)NRR' optionally substituted with R*; R a3 is selected from H, D, halogen, -CN, -NRR', -OR; R a5 is selected from H, D, halogen, -CN or C optionally substituted by R* 1-6 alkyl; R b2 is selected from H, D, halogen, -CN or C optionally substituted by R* 1-6 alkyl; R b3 is selected from H or D optionally substituted with R*; R b is H or D; n = 0, 1, 2, 3 or 4; R1 is C 1-6 alkyl; R5 is C 1-6 alkyl; R6 is C 1-6 alkyl; R* is H, halogen or -OH; R and R' are independently selected from H or C 1-6 alkyl.

26. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula (V-2): in, A1 is CR a1 or N; A2 is CR a2 or N; A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 or N; B2 is CR b2 or N; B3 is CR b3 or N; R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b2 , R b3 and R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R5 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R6 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula (VI-2): in, A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 or N; B2 is CR b2 or N; B3 is CR b3 or N; R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -C(O)R, -C(O)NRR', C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b2 , R b3 and R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R5 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R6 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

28. The compound of claim 26 or 27, or a pharmaceutically acceptable salt thereof, wherein R a1 , R a2 , R a3 , R a4 and R a5 independently selected from H, D, halogen, -CN, -NRR', -OR, -C(O)NRR', C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein the group is optionally substituted with one or more D or halogen, up to full substitution; R b2 , R b3 and R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted by one or more D or halogen, up to full substitution.

29. The compound of claim 26, or a pharmaceutically acceptable salt thereof, wherein A1 is CR a1 or N; A2 is CR a2 or N; A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 or N; B2 is CR b2 or N; B3 is CR b3 or N; R a1 , R a2 , R a3 , R a4 and R a5 is H, D, halogen, -CN, -NRR' or -OH; R b2 , R b3 and R b are independently selected from H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

30. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 or N; B2 is CR b2 or N; B3 is CR b3 or N; R a1 , R a2 , R a3 , R a4 and R a5 is H, D, halogen, -CN, -NRR' or -OH; R b2 , R b3 and R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; n = 0, 1, 2, 3 or 4; R1 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is H, D, halogen or C 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, D, -OH or halogen; R and R' are independently selected from H, D or C 1-6 Alkyl; wherein the C 1-6 The alkyl group is optionally substituted with one or more D or halogen, up to full substitution.

31. The compound of claim 29 or 30, or a pharmaceutically acceptable salt thereof, wherein There is at least one N among A3, A4 and A5.

32. The compound of claim 29 or 30, or a pharmaceutically acceptable salt thereof, wherein R b2 , R b3 and R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R1 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is H, D, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D up to full deuteration.

33. The compound of claim 26, or a pharmaceutically acceptable salt thereof, wherein A1 is CR a1 or N; A2 is CR a2 or N; A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 or N; B2 is CR b2 or N; B3 is CR b3 or N; R a1 and R a5 is H or D; R a3 is H, D or OH; R a2 and R a4 is H, D, halogen, -NRR' or -OH; R b2 , R b3 and R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; n = 0, 1, 2, 3 or 4; R1 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, halogen, -CN, -NRR' or -OR; R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 wherein the group is optionally substituted with one or more D, up to full deuteration.

34. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein A3 is CR a3 or N; A4 to CR a4 or N; A5 is CR a5 or N; B2 is CR b2 or N; B3 is CR b3 or N; R a1 and R a5 is H or D; R a3 is H, D or OH; R a2 and R a4 is H, D, halogen, -NRR' or -OH; R b2 , R b3 and R b are independently selected from H, D, halogen or C optionally substituted by R* 1-6 Alkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; n = 0, 1, 2, 3 or 4; R1 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R5 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R6 is C 1-6 Alkyl or C 1-6 Haloalkyl, wherein the group is optionally substituted with one or more D, up to full deuteration; R* is H, halogen or -OH; R and R' are independently selected from H, C 1-6 Alkyl and C 1-6 wherein the group is optionally substituted with one or more D, up to full deuteration.

35. The compound of claim 33 or 34, or a pharmaceutically acceptable salt thereof, wherein There is at least one N among A3, A4 and A5.

36. The compound of claim 33 or 34, or a pharmaceutically acceptable salt thereof, wherein R b2 , R b3 and R b are independently selected from H, D, halogen, -CN, C 1-6 Alkyl or C 1-6 Haloalkyl; R1 is C 1-6 Alkyl or C 1-6 Haloalkyl; R5 is C 1-6 Alkyl or C 1-6 Haloalkyl; R6 is C 1-6 Alkyl or C 1-6 Halogenated alkyl.

37. The compound of claim 36, or a pharmaceutically acceptable salt thereof, wherein R1 is methyl.

38. The compound of claim 36, or a pharmaceutically acceptable salt thereof, wherein R5 is methyl or -CF3.

39. The compound of claim 36, or a pharmaceutically acceptable salt thereof, wherein R6 is methyl or -CF3.

40. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the following general structure: in, Each group has the same definition as in claim 1.

41. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the following general structure: in, Each group has the same definition as in claims 1 and 2.

42. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the following general structure: in, Each group has the same definition as in claims 1 and 2.

43. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the following general structure: in, Each group has the same definition as in claims 1 and 2.

44. The compound of claim 1 selected from the group consisting of:

45. A pharmaceutical composition comprising a compound according to any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

46. ​​The pharmaceutical composition of claim 45, wherein It may also contain other therapeutic agents.

47. Use of a compound according to any one of claims 1 to 44 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 45 or 46 in the preparation of a medicament for treating and / or preventing ATR kinase-mediated diseases.

48. The use of claim 47, wherein the ATR kinase-mediated disease is a proliferative disease.

49. The use of claim 48, wherein the proliferative disease is cancer.

50. The use according to claim 49, wherein the cancer is a solid tumor, leukemia or lymphoma.

51. The use of claim 50, wherein the solid tumor is a sarcoma.

52. The use of claim 47, wherein the ATR kinase-mediated disease is selected from breast cancer, colorectal cancer, lung cancer and prostate cancer and bile duct cancer, bone cancer, bladder cancer, head and neck cancer, kidney cancer, liver cancer, gastrointestinal tissue cancer, esophageal cancer, ovarian cancer, pancreatic cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, cervical cancer and vulvar cancer, as well as leukemia, multiple myeloma and lymphoma.

53. The use of claim 52, wherein the lung cancer is selected from the group consisting of small cell lung cancer, non-small cell lung cancer and bronchioloalveolar carcinoma.

54. The use of claim 52, wherein the leukemia is selected from the group consisting of acute lymphocytic leukemia and chronic myeloid leukemia.